


1271105



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 08, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/509,700

FILING DATE: *October 08, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/33255*



Certified By

Jon W Dudas

**Under Secretary
of Commerce for Intellectual Property
and Acting Director of the
United States Patent and Trademark Office**

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 323287557 US

22582 U.S. PTO
60/509700

| INVENTOR(S) | | | | | |
|--|------------------------|---|--|---|--|
| Given Name (first and middle (if any)) | Family Name or Surname | Residence (City and either State or Foreign Country) | | | |
| G. Patrick Aiping | Meier Bai | Charleston, SC Charleston, SC | | | |
| <i>Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto</i> | | | | | |
| TITLE OF THE INVENTION (500 characters max) | | | | | |
| SITE AND RATE SELECTIVE PRODRUG FORMULATIONS OF D609 WITH ANTIOXIDANT AND ANTICANCER ACTIVITY | | | | | |
| Direct all correspondence to: CORRESPONDENCE ADDRESS | | | | | |
| <input checked="" type="checkbox"/> Customer Number: 32425 | | | | | |
| OR | | | | | |
| <input checked="" type="checkbox"/> Firm or Individual Name: FULBRIGHT & JAWORSKI L.L.P. | | | | | |
| Address: 600 Congress Ave., Ste. 2400 | | | | | |
| Address: | | | | | |
| City: Austin | | State: TX | | Zip: 78701 | |
| Country: U.S.A. | | Telephone: 512-474-5201 | | Fax: 512-536-4598 | |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | | | |
| <input checked="" type="checkbox"/> Specification Number of Pages <u>71</u> <input type="checkbox"/> CD(s), Number <u> </u> | | | | | |
| <input checked="" type="checkbox"/> Drawing(s) Number of Sheets <u>16</u> <input checked="" type="checkbox"/> Other (specify) <u>Fee Transmittal; \$80.00; postcard</u> | | | | | |
| <input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76 | | | | | |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT | | | | | |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. | | | | | |
| <input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees. | | | | | |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>50-1212/MESC:009USP1</u> | | | | | |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. | | | | | |
| <div style="display: flex; align-items: center;"> <div style="margin-right: 20px;">FILING FEE Amount (\$)</div> <div style="border: 1px solid black; padding: 10px; text-align: center; width: 100px;">80.00</div> </div> | | | | | |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. | | | | | |
| <input type="checkbox"/> No. | | | | | |
| <input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: <u>CA 78688 and CA 86860</u> <small>from the NIH and a research grant from the Department of Defense through the Hollings Cancer Center</small> | | | | | |

[Page 1 of 2]

Respectfully submitted,

Date 10/08/2003

SIGNATURE

Monica De La PazREGISTRATION NO. 54,662TYPED or PRINTED NAME Monica A. De La Paz

(if appropriate)

Docket Number: MESC:009USP1TELEPHONE (512) 474-5201**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROVISIONAL APPLICATION COVER SHEET
Additional Pag

PTO/SB/16 (08-03)

Approved for use through 07/31/2008. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number **MESC:009USP1**

| INVENTOR(S)/APPLICANT(S) | | |
|--|-------------------|---|
| Given Name (first and middle [if any]) | Family or Surname | Residence (City and either State or Foreign Country) |
| Daohong | Zhou | Mt. Pleasant, SC |

[Page 2 of 2]

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

17224 U.S. PAT.

PTO/SB/17 (01-03)

Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 80.00

Complete if Known

| | |
|----------------------|-----------------------|
| Application Number | Unknown |
| Filing Date | Concurrently Herewith |
| First Named Inventor | G. Patrick Meier |
| Examiner Name | Unknown |
| Art Unit | Unknown |
| Attorney Docket No. | MESC:009USP1 |

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account:

Deposit Account Number: 50-1212/MESC:009USP1
Deposit Account Name: FULBRIGHT & JAWORSKI LLP

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

| Large Entity Fee Code (\$) | Small Entity Fee Code (\$) | Fee Description | Fee Paid |
|-------------------------------|-------------------------------|------------------------|-----------|
| 1001 750 | 2001 375 | Utility filing fee | |
| 1002 330 | 2002 165 | Design filing fee | |
| 1003 520 | 2003 260 | Plant filing fee | |
| 1004 750 | 2004 375 | Reissue filing fee | |
| 1005 160 | 2005 80 | Provisional filing fee | 80.00 |
| SUBTOTAL (1) | | | (\$ 80.00 |

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

| Total Claims | Extra Claims | Fee from below | Fee Paid |
|--------------------|--------------|----------------|----------|
| Independent Claims | -20** = | X | |
| Multiple Dependent | -3** = | X | |

| Large Entity Fee Code (\$) | Small Entity Fee Code (\$) | Fee Description |
|-------------------------------|-------------------------------|--|
| 1202 18 | 2202 9 | Claims in excess of 20 |
| 1201 84 | 2201 42 | Independent claims in excess of 3 |
| 1203 280 | 2203 140 | Multiple dependent claim, if not paid |
| 1204 84 | 2204 42 | ** Reissue independent claims over original patent |
| 1205 18 | 2205 9 | ** Reissue claims in excess of 20 and over original patent |

SUBTOTAL (2) (\$)

**or number previously paid, if greater. For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

| Large Entity Fee Code (\$) | Small Entity Fee Code (\$) | Fee Description | Fee Paid |
|-------------------------------|-------------------------------|--|----------|
| 1051 130 | 2051 65 | Surcharge - late filing fee or oath | |
| 1052 50 | 2052 25 | Surcharge - late provisional filing fee or cover sheet | |
| 1053 130 | 1053 130 | Non-English specification | |
| 1812 2,520 | 1812 2,520 | For filing a request for ex parte reexamination. | |
| 1804 920* | 1804 920* | Requesting publication of SIR prior to Examiner action | |
| 1805 1,840* | 1805 1,840* | Requesting publication of SIR after Examiner action | |
| 1251 110 | 2251 55 | Extension for reply within first month | |
| 1252 410 | 2252 205 | Extension for reply within second month | |
| 1253 930 | 2253 465 | Extension for reply within third month | |
| 1254 1,450 | 2254 725 | Extension for reply within fourth month | |
| 1255 1,970 | 2255 985 | Extension for reply within fifth month | |
| 1401 320 | 2401 160 | Notice of Appeal | |
| 1402 320 | 2402 160 | Filing a brief in support of an appeal | |
| 1403 280 | 2403 140 | Request for oral hearing | |
| 1451 1,510 | 1451 1,510 | Petition to institute a public use proceeding | |
| 1452 110 | 2452 55 | Petition to revive - unavoidable | |
| 1453 1,300 | 2453 650 | Petition to revive - unintentional | |
| 1501 1,300 | 2501 650 | Utility issue fee (or reissue) | |
| 1502 470 | 2502 235 | Design issue fee | |
| 1503 630 | 2503 315 | Plant issue fee | |
| 1460 130 | 1460 130 | Petitions to the Commissioner | |
| 1807 50 | 1807 50 | Processing fee under 37 CFR 1.17(q) | |
| 1806 180 | 1806 180 | Submission of Information Disclosure Stmt | |
| 8021 40 | 8021 40 | Recording each patent assignment per property (times number of properties) | |
| 1809 750 | 2809 375 | Filing a submission after final rejection (37 CFR 1.129(a)) | |
| 1810 750 | 2810 375 | For each additional invention to be examined (37 CFR 1.129(b)) | |
| 1801 750 | 2801 375 | Request for Continued Examination (RCE) | |
| 1802 900 | 1802 900 | Request for expedited examination of a design application | |

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

(Complete if applicable)

| | | | | | |
|-------------------|---------------------|-----------------------------------|------------|-----------|--------------|
| Name (Print/Type) | Monica A. De La Paz | Registration No. (Attorney/Agent) | 54,662 | Telephone | 512-474-5201 |
| Signature | Monica A. De La Paz | Date | 10/08/2003 | | |

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PATENT
MESC:009USP1

PROVISIONAL APPLICATION FOR UNITED STATES LETTERS PATENT
for
SITE AND RATE SELECTIVE PRODRUG FORMULATIONS OF D609 WITH
ANTIOXIDANT AND ANTICANCER ACTIVITY
by
G. Patrick Meier, Aiping Bai
and
Daohong Zhou

| | |
|-----------------------------------|------------------------|
| <u>EXPRESS MAIL MAILING LABEL</u> | |
| NUMBER | <u>EV 323287557 US</u> |
| DATE OF DEPOSIT | <u>October 8, 2003</u> |

BACKGROUND OF THE INVENTION

The government owns rights in the present invention pursuant to grant numbers CA 78688 and CA 86860 from the NIH and a research grant from the Department of Defense through the Hollings Cancer Center.

5 1. Field of the Invention

The present invention relates generally to the fields of organic chemistry, pharmacology, pathology, and cancer biology. More particularly, it concerns derivatives of tricyclodecan-9-yl-xanthogenate, and methods of treating a disease and methods of protecting normal tissues in a subject from toxicity associated ionizing radiation or
10 chemotherapy.

2. Description of Related Art

Although many advances have been made in the therapy of human disease, treatments associated with significant toxicity, such as ionizing radiation (IR) and chemotherapy, are commonly used as therapeutic agents. The side effects of these forms
15 of therapy constitute a major limitation for IR and chemotherapy, thus presenting a great challenge and opportunity to develop improved therapies with less toxicity.

Several approaches have been taken to address this challenge. One approach is to develop molecularly targeted therapies that are based on an increased understanding of the molecular mechanisms that underlie the disease process, such as neoplastic
20 transformation in the case of cancer (Druker and Lydon, 2000; Gazdar and Minna, 2001; Gibbs, 2000). Other approaches include cytoprotectants that preferentially protect normal tissue from the toxic effects of these therapies, or sensitizers that make the diseased cells more sensitive than normal cells to IR and chemotherapy (Poggi *et al.*, 2001; Greenberger *et al.*, 2001). The goal of this approach is to enhance or preserve the
25 therapeutic efficacy of IR and chemotherapy against diseased cells while minimizing their toxicity in normal tissues, thus increasing the therapeutic of these conventional modalities.

Tricyclodecan-9-yl-xanthogenate (D609) is a member of the family of compounds called xanthates (Rao, 1971). Xanthates are strong electrolytes, and readily

dissociate to xanthate anions in solution. Xanthate anions and xanthic acid contain the xanthate moiety, which is a highly reductive group. Thus, D609 is a potent biological antioxidant.

5 Recently, it has been discovered that D609 is a potent biological antioxidant. In addition, D609 can also function as a potent cytoprotectant of normal cells from IR-induced oxidative damage (Zhou *et al.*, 2001). Mouse splenic lymphocytes pre-treated with D609 displayed a significant reduction in IR-induced reactive oxygen species (ROS) production, and protein and lipid peroxidation. Moreover, after exposure to IR, levels of intracellular reduced glutathione (GSH) declined in untreated lymphocytes but remained
10 steady in the cells treated with D609 (Li *et al.*, 1998).

There is substantial evidence that D609 is a selective tumor cytotoxic agent. However, the mechanisms of action of D609 against tumor cells remain to be fully elucidated. D609 also functions as a potent chemopreventive agent, as shown in a two-stage mouse skin tumor model (Furstenberger *et al.*, 1989). Unfortunately, D609
15 treatment exhibits only moderate antitumor activity *in vivo*. This may in part be related to poor pharmacokinetics.

Oxidative stress is a common etiology for many human diseases, including neurodegenerative diseases, diseases associated with ischemia and reperfusion injury, trauma, arteriosclerosis, aging, cancer, and tissue injury caused by various DNA damaging
20 agents, including UV radiation, ionizing radiation, and chemotherapeutic agents. Being a potent antioxidant and cytoprotectant, D609 has the potential to be used as a therapeutic agent for the treatment of these diseases. Indeed, it has been found that D609 pretreatment protected mice from ionizing radiation-induced death and dramatically reduced the infarct volume in the brains of mice subjected to cerebral ischemia and
25 reperfusion injury in a murine stroke model (Yu *et al.*, 2000).

Furthermore, D609 is a potent antiviral and anti-inflammatory agent. It can inhibit the activation of NF- κ B and the expression/production of various inflammatory molecules and cytokines. Thus, it has been used as an experimental therapeutic agent for various viral and bacterial diseases, autoimmune diseases, and inflammatory diseases.

30 Although D609 poses a great therapeutic potential, its use as a therapeutic agent is very limited. For example, D609 is a potent tumor cell cytotoxic agent *in vitro*.

However, D609 treatment exhibits only moderate antitumor activity *in vivo*. The disparity between the *in vitro* and *in vivo* antitumor activities of D609 may reflect its poor pharmacokinetics.

5 A “prodrug” is a pharmacologically inactive compound that can be converted into an active drug by metabolizing enzymes in the body, by non-metabolic reactions, or by utilizing both strategies (Smith and Clark, 1998). Prodrug modification of an active drug can be achieved by attaching a metabolically labile group that blocks the active site of the drug. This can be used to protect the pharmacore of a reactive compound, which leads to decreased metabolic inactivation and increased chemical stability of the compound.
10 Ultimately, this can result in the improvement of the pharmacokinetics, safety, and therapeutic efficacy of the active compound. The xanthate moiety of D609 can be easily oxidized to form a disulfide bond, with subsequent loss of its biological activities (Rao, 1971; Zhou *et al.*, 2001; Giron-Calle *et al.*, 2002). This oxidative instability of D609 may contribute to its poor antitumor activity *in vivo* (Amtmann and Sauer, 1990; Sauer *et al.*,
15 1990; Schick *et al.*, 1989).


Therefore, the development of novel compounds that are prodrugs of D609, in which the xanthate moiety is protected, may lead to greater therapeutic efficacy of D609. These compounds may result in increased stability of D609, and improved pharmacokinetics and therapeutic efficacy of D609 as a therapeutic agent in the treatment
20 of a wide range of disease processes, such as cancer and viral infection. Prodrug modification of D609 could also increase the efficacy of D609 as an antioxidant and as a cytoprotectant to protect normal healthy tissue. Thus, novel compounds that are prodrug modifications of D609 have the potential to provide dual therapeutic benefit against cancer, viral infection, and other diseases while concurrently protecting healthy tissue.

25 SUMMARY OF THE INVENTION

The inventors have discovered that S-modification of D609 through a metabolically labile linkage will protect the xanthate moiety as the pharmacore of D609, resulting in increased oxidative stability, improved pharmacokinetics, and enhanced therapeutic efficacy of the drug. The metabolically labile linkage is the linkage of a
30 heteroatom substituted alkyl moiety with the sulfhydryl moiety of D609. Examples of

such heteroatom substituted alkyl moieties that have been found to protect the pharmacore of D609 include an alkoxyphosphoryl moiety and an alkoxyacyl moiety. These novel agents can be applied in new forms of treatment of diseases and conditions, such as cancer, radiation damage, and diseases associated with oxidative stress. These agents can also be used to protect normal tissue in a subject from the toxicity associated with treatment of a disease with ionizing radiation or a chemotherapeutic agent. In addition, these agents can be applied as a novel secondary therapy in the treatment of disease, such as cancer.

Certain embodiments of the present invention are generally concerned with compounds of formula (I):




(I)


wherein R is a heteroatom substituted alkyl moiety, or a pharmaceutically acceptable salt thereof. The definition of heteroatom substituted alkyl moiety and pharmaceutically acceptable salt are discussed in detail in the specification below. The compounds of the present invention include a D609 moiety. D609 is discussed in the specification below. The compounds of the present invention include all geometrical and optical isoforms, including all geometrical and optical isoforms of D609 and variants of D609. The potassium salt of D609 is shown in FIG. 1A. The D609 moiety has three chiral centers, denoted by asterisks in FIG. 1A. As indicated by the dotted lines in the chemical structures depicted throughout this specification, the compounds of the present invention may include single enantiomers or racemic mixtures of each of the geometrical isomers and optical configurations of the claimed compound. One of ordinary skill in the art would be able to determine whether specific enantiomers have therapeutic or prophylactic activity, and would be able to synthesize a particular enantiomer.

In certain embodiments, R is an alkyl or alkoxy moiety. For example, the alkoxy moiety may be an alkoxyphosphoryl moiety or an alkoxyacyl moiety. In certain embodiments, the compound of formula (I) is:

5




wherein R¹, R², and R³ are independently H or alkyl moieties, or a pharmaceutically acceptable salt thereof. In further embodiments, the compound of formula (I) is:



10 wherein R¹ and R² are independently H or alkyl moieties, or a pharmaceutically acceptable salt thereof. The structure and other features of the compounds of the present invention are discussed in greater detail in elsewhere in the specification.

The present invention also pertains to pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable excipient. Pharmaceutical compositions and pharmaceutically acceptable excipients are well-known to those of
15 ordinary skill in the art, and are discussed in greater detail elsewhere in the specification.

Methods of treating a disease or disorder in a subject are also contemplated by the present invention, including: (1) obtaining a composition comprising a compound of formula (I):



(I)

wherein R is a heteroatom substituted alkyl moiety, or a pharmaceutically acceptable salt thereof; and (2) administering a therapeutically effective amount of the composition to the subject. In certain embodiments, R is an alkyl or alkoxy moiety. For example, the alkoxy moiety may be an alkoxyphosphoryl or alkoxyacyl moiety. The examples of compounds wherein R is an alkoxyphosphoryl or alkoxyacyl moiety that were discussed above also apply to these methods.

In certain embodiments of the present methods, the subject is a mammal. For example, the mammal may be a human. The definition of disease or disorder is discussed elsewhere in the specification. Any disease or disorder is contemplated by the present invention. For example, the disease may be an autoimmune disease, and inflammatory disease, a neurodegenerative disease, a disease associated with ischemia and reperfusion injury, trauma, atherosclerosis, ageing, cancer, viral infection, UV-induced radiation injury, or ionizing radiation-induced injury. One of ordinary skill in the art would be familiar with the diseases that fall within each of these categories.

For example, the autoimmune disease may be systemic lupus, chronic thyroiditis, Graves disease, autoimmune gastritis, autoimmune hemolytic anemia, autoimmune neutropenia, or thrombocytopenia. The inflammatory disease may be rheumatoid arthritis, organ transplant rejection, graft versus host disease, endotoxemia, sepsis, septic shock, uveitis, inflammatory peritonitis, or pancreatitis. The neurodegenerative disease may be Alzheimer disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, multiple sclerosis, amyotrophic lateral sclerosis, or spinal muscular atrophy. The disease associated with ischemia and reperfusion injury may be a stroke or myocardial infarction.

The methods of the present invention can also be applied in the treatment of cancer. Any type of cancer is contemplated for treatment by the methods of the present invention. One of ordinary skill in the art would be familiar with the many types of

cancers that are known which would be amenable to treatment. For example, the cancer may be breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, leukemia, stomach cancer, pancreatic cancer, testicular cancer lymphoma, or multiple myeloma. The cancer may be localized cancer, locally invasive cancer, or metastatic disease.

Tissue destruction associated with trauma is also contemplated for treatment by the present methods. Any type of traumatic tissue damage is contemplated for treatment by the methods of the present invention. For example, the trauma may be traumatic brain injury, spinal cord injury, or burn injury. In addition, the disease or disorder may be a condition that is associated with oxidative stress. Any condition associated with oxidative stress is contemplated for treatment.

In some embodiments, the methods of the present invention also include methods of targeting delivery of a therapeutic amount of the composition to a site of disease in a subject by release of the active agent at the site of disease following administration. The active agent is released by phosphatase, esterase, or amidase activity at the site of disease following administration. The released active agent then scavenges reactive species (including oxygen and nitrogen radicals), inhibits phosphatidylcholine-specific phospholipase C (PC-PLC) and enzymes involved in sphingolipid metabolism (such as sphingomyelin synthase and various ceramidases), suppresses NF- κ B activity, and decreases the production of various inflammatory molecules and cytokines.

Administration of the compositions can be by any method known to those of ordinary skill in the art. For example, the therapeutic amount of the composition can be administered by oral administration, intravenous administration, intraarterial administration, topical administration, intratumoral administration, regional administration, intrathecal administration, intraperitoneal administration, intraocular administration, or inhalational administration.

The present invention also concerns methods of protecting normal tissue in a subject from the toxicity associated with treatment of a disease with ionizing radiation or a chemotherapeutic agent, including: (1) obtaining a compound of formula (I) as discussed above, and (2) concurrently or consecutively administering to the subject a

prophylactically effective amount of the composition and the ionizing radiation or chemotherapeutic agent. The structural features of formula (I) discussed above also apply to this section. For example, R can be an alkyl or alkoxy moiety. The alkoxy moiety may include, for example, an alkoxyphosphoryl or alkoxyacyl moiety. The examples of compounds previously disclosed also apply to these particular methods.

As noted above, the subject may be a mammal, such as a human. The toxicity may be associated with treatment of any disease, such as an autoimmune disease, and inflammatory disease, a neurodegenerative disease, a disease associated with ischemia and reperfusion injury, trauma, atherosclerosis, ageing, cancer, or a viral infection. Examples of these diseases discussed above also apply to these particular methods.

The definition of chemotherapeutic agent is detailed in the specification below. In certain embodiments, the chemotherapeutic agent is doxorubicin, daunorubicin, methotrexate, tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etoposide, tomudex, podophyllotoxin, mitoxantrone, colchicine, endostatin, fludarabin, mitomycin, actinomycin D, bleomycin, cisplatin, VP16, an enediyne, taxol, vincristine, vinblastine, carmustine, melphalan, cyclophosphamide, chlorambucil, busulfan, lomustine, 5-fluorouracil, gemcitabine, BCNU, or camptothecin.

Administering a prophylactically effective amount of the composition includes any route or method of administration. Examples include oral administration, intravenous administration, intraarterial administration, topical administration, local administration into a tumor, intrathecal administration, intraperitoneal administration, intraocular administration, or inhalational administration. One of ordinary skill in the art would be familiar with the range of methods of administering a composition that are available. The methods of protecting normal tissue in a subject can also concurrently include targeting delivery of a therapeutic amount of the composition to a site of disease in the subject, as discussed above in relation to therapeutic methods involving the claimed compositions.

A prophylactically effective amount of the composition is an amount that is expected to prevent the development of a particular disease or condition in a subject. The prophylactically effective amount of the composition may be administered concurrently or consecutively with the ionizing radiation or chemotherapeutic agent. The definitions

of concurrent and consecutive administration are discussed in detail elsewhere in the specification, and apply to this section. In certain embodiments, the prophylactically effective amount of the composition and the ionizing radiation or chemotherapeutic agent are concurrently administered. In other embodiments, the prophylactically effective amount of the composition and the ionizing radiation or chemotherapeutic agent are consecutively administered. One of ordinary skill in the art would be familiar with techniques to determine the amount of a dose to be administered such that it is prophylactically effective.

Further embodiments of the present invention pertain to methods of treating a disease or disorder in a subject, including: (1) obtaining a composition that includes a compound of formula (I) disclosed above; and (2) concurrently or consecutively administering a therapeutically effective amount of the composition and ionizing radiation or a chemotherapeutic agent to the subject. The compounds of formula (I) disclosed in previous parts of this summary also apply to these methods. For example, in some embodiments, R in formula (I) is an alkyl or alkoxy moiety, such as an alkoxylphosphoryl moiety or an alkoxyacyl moiety.

These methods can be applied to any subject. In certain embodiments, the subject is a mammal. More particularly, the subject may be a human subject. Treatment of any disease or disorder is contemplated by the present invention. Examples of these diseases disclosed in reference to other methods in this summary also apply to these particular methods. For example, the disease may be a cancer, such as breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, leukemia, stomach cancer, pancreatic cancer, testicular cancer lymphoma, or multiple myeloma.

As noted above, any method of administration of the therapeutically effective amount of the composition is contemplated by the present invention. Examples of these methods have been previously discussed, and are also discussed elsewhere in this specification. In certain embodiments, the therapeutically effective amount of the composition and the ionizing radiation or chemotherapeutic agent are concurrently administered. In still other embodiments, the therapeutically effective amount of the

composition and the ionizing radiation or chemotherapeutic agent are consecutively administered. Concurrent and consecutive administration have been previously discussed.

5 One of ordinary skill in the art would be able to determine the amount of the composition to be administered such that a therapeutic effect is achieved. A therapeutically effective amount of the composition is an amount that is expected to prevent progression or result in improvement in the disease or disorder, or to otherwise achieve a desired therapeutic effect.

10 As used herein the specification, "a" or "an" may mean one or more. As used herein in the claim(s), when used in conjunction with the word "comprising", the words "a" or "an" may mean one or more than one. As used herein "another" may mean at least a second or more.

15 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

20 The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

25 **FIG. 1A, FIG. 1B, FIG. 1C.** FIG. 1A - Chemical structure of the potassium salt of one of the isomers of D609; FIG. 1B – chemical structure of one isomer of S-(Alkoxyphosphoryl) D609; FIG. 1C – chemical structure of one isomer of S-(Alkoxyacyl) D609.

FIG. 2. The main metabolic pathway of D609.

FIG. 3. Cyclic voltammetry of D609.

30 **FIG. 4A, FIG. 4B.** D609 protects mice from IR-induced lethality.

FIG. 5A, FIG. 5B. D609 selectively induces tumor cell death by apoptosis.

FIG. 6A, FIG. 6B, FIG. 6C. D609 enhances mouse splenic lymphocyte mitogenic responses and IFN γ production.

FIG. 7A, FIG. 7B, FIG. 7C. Comparison of the effects of D609, cyclohexyl xanthate, and tricyclodecanol on PC-PCLbc, SMS and U937 cell viability.

FIG. 8A, FIG. 8B, FIG. 8C, FIG. 8D. D609 inhibits cellular SMS activity and induces changes in the cellular levels of ceramide and DAG in U937 cells.

FIG. 9. Ceramide and H7 synergistically induce U937 cell apoptosis.

FIG. 10. PMA attenuates D609-induced U937 cell apoptosis.

FIG. 11A, FIG. 11B. Effects of D609 and/or IR on A20 cell viability and growth *in vitro*.

FIG. 12A, FIG. 12B. Lack of significant therapeutic effects of D609 and/or IR on A20 lymphoma *in vivo*.

FIG. 13. The synthesis scheme for the alkoxyphosphoryl prodrug herein designated as compound 7.

FIG. 14. Synthesis scheme of the alkoxyacyl prodrugs.

FIG. 15. Scheme demonstrating hydrolysis of D609 prodrugs by alkaline phosphatase or esterase activity.

FIG. 16A, FIG. 16B, FIG. 16C. **FIG. 16A** – structure of S-(methylenoxyacetyl) D609 (herein compound 22); **FIG. 16B** – structure of S-(methylenoxy-(2,2-dimethylacetyl)) D609 (herein compound 26); **FIG. 16C** – structure of S-(methylenoxy)-D609, di(^tbutoxy) phosphate (herein compound 7).

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention seeks to exploit the inventors' discovery by providing for novel compounds that are heteroatom substituted alkyl derivatives of tricyclodecan-9-yl-xanthogenate (D609). D609 was originally developed as an antitumor and antiviral agent. These novel compounds have increased oxidative stability and are expected to have improved pharmacokinetics and enhanced therapeutic efficacy compared to D609.

These novel compounds can be applied as novel therapeutic agents in the treatment of a wide range of diseases, including autoimmune diseases, inflammatory

diseases, neurodegenerative diseases, diseases associated with ischemia and reperfusion injury, trauma, atherosclerosis, ageing, cancer, viral infection, and UV and ionizing radiation-induced injury and tissue damage. In addition, these compounds not only have enhanced therapeutic efficacy compared to D609, but they also can protect normal tissue and are potent antioxidants.

A. Tricyclodecan-9-yl-xanthogenate (D609) and Prodrugs of D609

1. D609

As used herein, tricyclodecan-9-yl-xanthogenate, or D609, refers not only to the xanthate derivative of D609, but also refers to any xanthate anion of D609, which may include a cation of an alkali metal. Any cation of an alkali metal is contemplated for inclusion in the definition of D609. Although the compound known as D609 is the C-endo, O-exo isomer, the claimed compounds of the present invention are herein more broadly defined to include any and all geometrical and optical isomers of D609 and variants of D609. FIG. 1A depicts one example of D609, which is a potassium salt of D609. The three chiral centers are designated by asterisks in FIG. 1A. As indicated by the dotted lines in the structures depicted throughout this specification, the compounds of the present invention may include single enantiomers or racemic mixtures of each of the geometrical isomers and optical configurations of the claimed compounds. The compounds of the claimed invention include any and all optical and geometrical isomers.

D609 is a member of the family of compounds called xanthates, which are formed by the reaction of carbon disulfide, an alcohol, and an alkali in an equal stoichiometric ratio with elimination of water. Xanthates have the general structure: ROCS_2M , where R stands for an alkyl hydrocarbon moiety and M denotes a monovalent cation such as potassium. Xanthates are strong electrolytes, and readily dissociate to xanthate anions (and cations of alkali metals) in solution.

Upon reacting with an oxidant, xanthates are oxidized to dioxanthogens, which contain a disulfide bond (Rao, 1971), which implies that D609 and other xanthate derivatives can function as potent biological antioxidants. This assumption is supported by the finding that D609 effectively inhibits hydroxyl radical-mediated oxidation of dihydrorhodamine 123 (DHR) in a dose-dependent manner (Zhou *et al.*, 2001). In addition, D609 inhibits the formation of the α -phenyl-tert-butyl nitron (PBN)-free

radical spin adducts and lipid peroxidation of synaptosomal membranes by hydroxyl radical (Zhou *et al.*, 2001).

GSH is one of the major intracellular defense molecules against oxidative stress and also has been shown to play an important role in radiation protection (Hospers *et al.*, 1999). Maintenance of a steady level of intracellular GSH by D609 may contribute to the suppression of IR-induced oxidative damage. In addition, D609 could protect normal cells from IR-induced damage by inhibiting phosphatidylcholine-specific phospholipase C (PC-PLC). By inhibiting PC-PLC, D609 could reduce the production of diacylglycerol (DAG) that is coupled to the activation of acidic sphingomyelinase (aSMase) and the subsequent production of ceramide via hydrolysis of sphingomyelin by aSMase, and thus, protect normal cells, particularly endothelial cells, from IR-induced apoptosis (Schutze *et al.*, 1991; Schutze *et al.*, 1992; Paris *et al.*, 2001; Santana *et al.*, 1996).

Importantly, D609 does not protect tumor cells from IR-induced cell death, nor does it protect tumor cells from chemotherapeutic agent-induced apoptosis (Bettaieb *et al.*, 1999). These findings indicate that D609 has the ability to selectively protect normal cells but not tumor cells from IR- and chemotherapeutic agent-induced cytotoxicity. The mechanisms that underlie the difference between normal cells and tumor cells in their response to D609-mediated cytoprotection have yet to be determined.

There is substantial evidence that D609 is a selective tumor cytotoxic agent. The list of transformed and malignant cell types that are sensitive to D609 toxicity is expanding and now includes bovine papilloma virus type 1 (BPV-1)- and SV40-transformed animal and human fibroblasts, various leukemia/lymphoma cells and different solid tumor cells with only a few exceptions (Amtmann and Sauer, 1987; Porn-Ares *et al.*, 1997; Schick *et al.*, 1989; Enomoto *et al.*, 2000). Even some drug-resistant tumor cells, such as methotrexate- and adriamycin-resistant L1210 and S180 cells, are susceptible to D609 cytotoxicity (Schick *et al.*, 1989).

In contrast, under the same *in vitro* cell culture conditions, D609 did not show any cytotoxicity against normal human fibroblasts or peripheral blood lymphocytes (Amtmann and Sauer, 1987). In fact, D609 enhances mitogen-stimulated mouse splenic lymphocyte proliferation and cytokine production. These observations suggest that unlike other known chemotherapeutic agents that usually inhibit tumor cell growth and

induce tumor cell death nonspecifically by inhibiting DNA replication or inducing DNA damage, the antitumor effect of D609 is likely the result of inhibition of a tumor-specific target.

However, the mechanisms of action of D609 against tumor cells remain to be fully elucidated. Originally, it was suggested that D609 functions as a specific inhibitor of the phosphatidylcholine-specific phospholipase C (PC-PLC), mainly based on *in vitro* cell-free studies using the bacterial enzyme (Amtmann, 1996; Schutze *et al.*, 1992). PC-PLC utilizes phosphatidylcholine (PC) as substrate and hydrolyzes PC to produce diacylglycerol (DAG) and phosphocholine (PhoCho) (Schutze *et al.*, 1992; Machleidt *et al.*, 1996; Schutze *et al.*, 1991). Recently, it was reported that D609 also inhibits SMS which transfers the PhoCho group from PC to ceramide and produces DAG and sphingomyelin (SM) (Lubert and Hannun, 1998; Luberto *et al.*, 2000). These observations raise the possibility that SMS may account for some of the cellular effects that had been attributed to PC-PLC (Luberto and Hannun, 1998; Luberto *et al.*, 2000), because both enzymes utilize PC as substrate and produce DAG as one of their products.

D609 also functions as a potent chemopreventive agent, as shown in a two-stage mouse skin tumor model (Furstenberger *et al.*, 1989). Unfortunately, D609 treatment exhibits only moderate antitumor activity *in vivo*. This may in part be related to poor pharmacokinetics. As a xanthate derivative, D609 is relatively unstable in solution and in biological systems (Rao, 1971; Zhou *et al.*, 2001; Giron-Calle *et al.*, 2002). D609 can also be readily oxidized, resulting in loss of the xanthate moiety. Since the xanthate moiety functions as the pharmacore of D609 for many of its biological activities, a sufficient amount of D609 probably cannot reach the target tissue *in vivo* after administration. This oxidative instability of D609 may contribute to its poor antitumor activity *in vivo* (Amtmann and Sauer, 1990; Sauer *et al.*, 1990; Schick *et al.*, 1989).

2. Prodrugs

The compounds of the present invention are the prodrugs of D609. As depicted by the asterisks in FIG. 1A, the structure of D609 includes three chiral centers. As indicated by the dotted lines in the chemical structures depicted throughout this specification, the compounds of the present invention may include single enantiomers or racemic mixtures of each of the geometrical isomers and optical configurations of the claimed compounds.

One of ordinary skill in the art would be able to determine whether specific enantiomers have therapeutic or prophylactic activity, and would be able to synthesize a particular enantiomer. Examples of structures of compounds of the present invention include S-(alkoxyphosphoryl) D609 (FIG. 1B) and S-(alkoxyacyl) D609 (FIG. 1C) compounds.

5 The definition of D609 is defined herein to include all isomers of D609. As the compounds of the present invention include a D609 moiety, it holds true that the compounds of the present invention therefore include D609 moieties that are of a single isoform or different isoforms. The compounds of the claimed invention include any and all optical and geometrical isomers.

10 It is possible that particular isoforms of the compounds of the present invention have enhanced therapeutic activity compared to other isoforms. One of ordinary skill in the art would be able to synthesize enantiomers of the compounds, and determine which isoforms have therapeutic activity.

Any method known to those of ordinary skill in the art can be used to synthesize
15 D609 for use in synthesis of the compounds of the present invention. For example, one well-known method to synthesize D609 is described by Rao, 1971, which is herein specifically incorporated by reference. One of ordinary skill in the art would be familiar with other methods that can be used to synthesize D609.

Similarly, any method known to those of ordinary skill in the art can be used to
20 synthesize the compounds of the present invention, which include the D609 moiety. Particular methods of synthesis of compounds of the present invention are discussed in the examples below.

Recently, the alkoxyphosphoryl group has been developed as a prodrug
25 modification of a carboxylic acid and amine as a means for increasing the water solubility of lipophilic drugs (Nudelman *et al.*, 2001; Krise *et al.*, 1999a, Krise *et al.*, 1999b). This prodrug moiety was designed to release the active drugs via a two-step process. Alkaline phosphatase catalyzes the hydrolysis of the phosphate ester and the resulting hydroxymethyl ammonium salt rapidly reverts to formaldehyde and the amine.

3. Substituents

30 Certain embodiments of the present invention pertain to chemical formulas that include an R group moiety (see, *e.g.*, formulas disclosed in claims 1, 7, 23, and 37),

wherein R is a heteroatom substituted alkyl moiety. A heteroatom substituted alkyl moiety is a carbon chain of one or more carbons in which the linking carbon is bonded to an atom other than carbon or hydrogen in addition to the linking group functionality. In some embodiments, the heteroatom substituted alkyl moiety may further be defined as an alkane, an alkene, an alkyne, a diene, an arene, an alkyl halide, an alkenyl halide, or an aryl halide. In certain embodiments, R is an alkoxy moiety. The alkyl or alkoxy moiety can include any number of carbon atoms. For example, in some embodiments, the alkyl or alkoxy moiety includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, or more carbon atoms. In certain embodiments, the alkoxy moiety is an alkoxyphosphoryl moiety or an alkoxyacyl moiety. Certain embodiments of the present invention pertain to compounds that have chemical formulas wherein R is an alkoxyphosphoryl moiety or alkoxyacyl moiety that further includes a ligand designated R₁, R₂, or R₃. In these embodiments, R₁, R₂, or R₃ are independently H, alkyl, alkenyl, aryl moieties or pharmaceutically acceptable salts. Any type of alkyl moiety is contemplated for inclusion in the present invention. One of ordinary skill in the art would be familiar with the wide range of types of alkyl moieties that can be included in the compounds of the present invention.

For example, the alkyl moiety may be further defined as an alkane, an alkene, an alkyne, a diene, an arene, an alkyl halide, an alkenyl halide, or an aryl halide. The alkyl moiety may or may not be substituted. The present invention contemplates any type of substitution of the alkyl moiety. As discussed above, a compound of the present invention may comprise, but is not limited to, a diastereomer, an enantiomer, or a racemic mixture of stereoisomers.

4. Pharmaceutically Acceptable Salts

In certain embodiments, the compounds of the present invention pertain to pharmaceutically acceptable salts.

Non-toxic esters and salts which are generally prepared by reacting the free base with a suitable organic or inorganic acid are suitable for pharmaceutical use. Representative salts and esters include the following: Acetate, Lactobionate, Benzenesulfonate, Laurate, Benzoate, Malate, Bicarbonate Maleate, Bisulfate Mandelate, Bitartrate, Mesylate, Borate, Methylbromide, Bromide, Methylnitrate, Calcium Edetate,

Methylsulfate, Camsylate, Mucate, Carbonate, Napsylate, Chloride, Nitrate, Clavulanate, N-methylglucamine, Citrate, ammonium salt, Dihydrochloride, Oleate, Edetate, Oxalate, Edisylate, Pamoate (Embonate), Estolate, Palmitate, Esylate, Pantothenate, Fumarate, Phosphate/diphosphate, Gluceptate, Polygalacturonate, Gluconate, Salicylate, Glutamate, Stearate, Glycollylarsanilate, Sulfate, Hexylresorcinate, Subacetate, Hydrabamine, Succinate, Hydrobromide, Tannate, Hydrochloride, Tartrate, Hydroxynaphthoate, Teoate, Iodide, Tosylate, Isothionate, Triethiodide, Lactate, or Valerate. One of ordinary skill in the art would be familiar with these and other pharmaceutically acceptable salts that are contemplated by this invention.

The definition of “pharmaceutical” and “pharmaceutically acceptable” is defined below in this specification, and these definitions apply to this section of the specification.

B. Diseases and Disorders to be Treated

Treatment of any disease or disorder is contemplated by the methods of treatment of the present invention. “Treating” and “treatment” are broadly defined and includes for example a slowing or halting of the progression of a disease or disorder. For example, inhibiting the growth of a lesion, such as a tumor, can also include a reduction in the size of a lesion or induction of apoptosis of the cells of the lesion. One of ordinary skill in the art would be familiar with the slowing or halting of the progression of a disease or disorder.

As used herein, “disease” refers to a pathological condition of a body part, an organ, or a system resulting from various causes, such as infection, genetic defect, or environmental stress, or any other cause, and characterized by an identifiable group of signs or symptoms. As used herein, “disorder” refers to any disturbance or derangement that affects the function of the mind or body, or any disturbance of normal physical health. An example of a disorder would be aging. A disorder may or may not be associated with a group of signs and symptoms.

Examples of diseases and disorders that are contemplated for treatment include, but are not limited to, autoimmune diseases. Examples of autoimmune diseases include systemic lupus, chronic thyroiditis, Graves disease, autoimmune gastritis, autoimmune hemolytic anemia, autoimmune neutropenia, and thrombocytopenia. Inflammatory diseases are also contemplated for treatment. Examples of inflammatory diseases include

rheumatoid arthritis, organ transplant rejection, graft versus host disease, endotoxemia, sepsis, septic shock, uveitis, inflammatory peritonitis, and pancreatitis. Neurodegenerative diseases, such as Alzheimer disease, Parkinson's disease, Huntington's disease, Kennedy disease, prion disease, multiple sclerosis, amyotrophic lateral sclerosis, and spinal muscular atrophy, are also contemplated for treatment. Diseases associated with ischemia and reperfusion injury, such as stroke and heart attack, are also contemplated for treatment by the methods of the present invention. Other diseases that are contemplated for treatment include trauma, such as traumatic brain injury, spinal cord injury, and burn. Additional diseases and disorders that are contemplated for treatment by the methods of the present invention include atherosclerosis, aging, cancer, viral infection, and UV and ionizing-induced injury and tissue damage.

The cancer may be of any type of cancer, such as breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, leukemia, stomach cancer, pancreatic cancer, testicular cancer lymphoma, or multiple myeloma. The cancer may be localized cancer, locally invasive cancer, or metastatic disease.

Other diseases and disorders contemplated for treatment include any disease or disorder associated with oxidative stress, including neurodegenerative diseases, diseases associated with ischemia and reperfusion injury, trauma, arteriosclerosis, aging, cancer, and tissue injury caused by therapeutic agents, such as UV radiation, ionizing radiation, and chemotherapy.

C. Pharmaceutical Formulations

1. Overview

The present invention contemplates pharmaceutical compositions comprising compounds of the present invention in a pharmaceutically acceptable excipient. It also contemplates methods of treating a disease or disorder in a subject that include administering a therapeutically effective amount of a composition of the present invention to a subject. In addition, the present invention pertains to methods of

protecting normal tissue in a subject from the toxicity associated with treatment of a disease with ionizing radiation or a chemotherapeutic agent, which include concurrently or consecutively administering to the subject a prophylactically effective amount of the composition and the ionizing radiation or chemotherapeutic agent. The present invention
5 also pertains to methods of treating a disease or disorder in a subject that include concurrently or consecutively administering to the subject a therapeutically effective amount of the composition and ionizing radiation or a chemotherapeutic agent to the subject.

2. Administration

10 a. Routes of Administration

In the context of the claimed invention, “administering” is defined to include administration of the composition by any method known to those of ordinary skill in the art. Examples of routes of administration are further discussed in the Summary of the Invention. One of ordinary skill in the art would be familiar with the wide range of
15 routes of administration of a therapeutic composition that are available.

b. Concurrent Administration

Certain embodiments of the present invention pertain to methods that involve concurrent or consecutive administration of a prophylactically effective amount of the composition and ionizing radiation or a chemotherapeutic agent to protect normal tissue
20 in a subject from toxicity. Other embodiments of the present invention pertain to methods involving concurrent or consecutive administration of a therapeutically effective amount of the composition and ionizing radiation or a chemotherapeutic agent to a subject for treatment of a disease or disorder.

As used herein, “concurrent” is defined to mean initiation of administration of the therapeutic or prophylactic composition at about the same time as the ionizing radiation or chemotherapeutic agent. For example, in certain embodiments of the present invention, the administration of the therapeutically or prophylactically effective amount of the composition will begin at the same time, within about 1 minute, within about 2
30 minutes, within about 3 minutes, within about 4 minutes, within about 5 minutes, within about 6 minutes, within about 7 minutes, within about 8 minutes, within about 9 minutes,

within about 10 minutes, within about 12 minutes, within about 14 minutes, within about 16 minutes, within about 18 minutes within about 20 minutes, within about 25 minutes, within about 30 minutes, within about 35 minutes, within about 40 minutes, within about 45 minutes, within about 50 minutes, within about 55 minutes, or within about 60 minutes of beginning or ending a single dose of radiation or a chemotherapeutic agent, or any intermediate time within these intervals.

Administration of a chemotherapeutic agent is discussed further below. One of ordinary skill in the art would be familiar with administration of a chemotherapeutic agent. Some agents are administered in a single dose over a specific time interval, such as 20 minutes, 40 minutes, or over 1 hour. Other agents may be administered over a shorter interval, such as 5 minutes. One of ordinary skill in the art would be familiar with methods of administration of these agents, and time intervals over which these agents must be administered. Thus, concurrent administration of the therapeutic or prophylactic amount of the composition with the therapeutic administration may, in certain embodiments, involve beginning administration of the therapeutic agent during any time point while a single dose of the chemotherapeutic agent is being administered.

One of ordinary skill in the art would also understand that a course of a particular chemotherapeutic agent often involves administration of multiple doses of the chemotherapeutic agent over a period of time. For example, a course of a particular chemotherapeutic agent may involve administration of 3 doses of the agent over a period of three days, 1 week, or 2 weeks. One of ordinary skill in the art would be familiar with these regimens for administration of courses of different chemotherapeutic agents. Concurrent administration is thus also defined to include administration of a therapeutic or prophylactic amount of the composition at any point during the beginning and ending of a multiple dose course of therapy with a particular chemotherapeutic agent. For example, concurrent administration may include initiating administration of a course of a therapeutically effective amount of the composition on day 13 of a 15 day course of a particular chemotherapeutic agent.

The course of administration of the therapeutic or prophylactic composition may be a single dose or multiple doses. Concurrent administration does not require that the administration of the therapeutic or prophylactic amount of the composition be complete

prior to completion of the dose or course of chemotherapy or ionizing radiation. The definition only pertains to initiation of the administration of the therapeutic or prophylactic amount of the composition in relation to course of ionizing radiation or chemotherapeutic agent.

5 Various combinations of the composition and chemotherapeutic agent may be employed, for example, if the composition is "A" and the secondary agent, such as radio- or chemotherapy, is "B":

10 A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B
 B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A
 B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A

15 Administration of the compositions of the present invention to a patient will follow general protocols for the administration of chemotherapeutics, taking into account the toxicity, if any, of the vector. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that various standard therapies, as well as surgical intervention, may be applied in combination with the described therapies.

c. Consecutive Administration

20 Consecutive administration is defined herein to include beginning administration of the therapeutic or prophylactic amount of the composition of the present invention either before initiation of the therapy with the ionizing radiation or a chemotherapeutic agent, or following completion of a course of therapy with ionizing radiation or a chemotherapeutic agent. As noted above, a course of therapy with chemotherapy or ionizing radiation may involve multiple doses or administrations over a course of time.

25 Consecutive administration requires initiation of administration of the composition of the present invention either prior to beginning a course of administration of ionizing radiation or chemotherapy, or following completion of a course of ionizing radiation or a course of chemotherapy. Consecutive administration, as defined herein, requires that there be no overlap in the course of administration of the composition and the ionizing radiation or chemotherapeutic agent.

30

For example, in certain embodiments, consecutive administration involves administration of the prophylactically or therapeutically effective amount of the composition of the present invention to be complete within about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 6 hours, about 1 day, about 5 days, about 10 days, or about 30 days prior to initiation of a course of ionizing radiation or chemotherapy. Similarly, in other embodiments, consecutive administration involves beginning administration of the prophylactically or therapeutically effective amount of the composition of the present invention within about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 6 hours, about 1 day, about 5 days, about 10 days, or about 30 days after completion of a course of ionizing radiation or chemotherapy. These time intervals are only by way of example, and are not exhaustive. One of ordinary skill in the art would be familiar with the range of possible time intervals for either consecutive or concurrent administration of the composition with ionizing radiation or chemotherapy.

3. Pharmaceutical Compositions

The phrase “pharmaceutically acceptable” and “pharmaceutical” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. As used herein, “pharmaceutical composition” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients also can be incorporated into the composition. In addition, the composition can include supplementary inactive ingredients. For instance, the composition for use as a mouthwash may include a flavorant or the composition may contain supplementary ingredients to make the formulation timed-release.

Aqueous compositions of the present invention comprise an effective amount of the compound, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous

medium. Examples of aqueous compositions include a spray or aerosol, a solution for intravenous injection, or ophthalmic solution.

Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

Administration of therapeutic compositions according to the present invention will be via any common route so long as the target tissue is available via that route. For example, this includes oral, nasal, buccal, anal, rectal, vaginal, or topical ophthalmic. Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients.

The therapeutic and preventive compositions of the present invention are advantageously administered in the form of liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to topical use may also be prepared. A typical composition for such purpose comprises a pharmaceutically acceptable carrier. For instance, the composition may contain 10 mg, 25 mg, 50 mg or up to about 100 mg of human serum albumin per ml of phosphate buffered saline. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate. Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc. Preservatives include antimicrobial agents, anti-oxidants, chelating agents and inert gases. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to well-known parameters.

Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and/or the like. These compositions take the form of solutions such as mouthwashes and mouthrinses, suspensions, tablets, pills,

capsules, sustained release formulations and/or powders. In certain defined embodiments, oral pharmaceutical compositions will comprise an inert diluent and/or assimilable edible carrier, and/or they may be enclosed in hard and/or soft shell gelatin capsule, and/or they may be compressed into tablets, and/or they may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compounds may be incorporated with excipients and/or used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and/or the like. Such compositions and/or preparations should contain at least 0.1% of active compound. The percentage of the compositions and/or preparations may, of course, be varied and/or may conveniently be between about 2 to about 75% of the weight of the unit, and/or preferably between 25-60%. The amount of active compounds in such therapeutically useful compositions is such that a suitable dosage will be obtained.

The tablets, troches, pills, capsules and/or the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, and/or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and/or the like; a lubricant, such as magnesium stearate; and/or a sweetening agent, such as sucrose, lactose and/or saccharin may be added and/or a flavoring agent, such as peppermint, oil of wintergreen, and/or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings and/or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, and/or capsules may be coated with shellac, sugar and/or both. A syrup or elixir may contain the active compounds sucrose as a sweetening agent methyl and/or propyl parabens as preservatives, a dye and/or flavoring, such as cherry and/or orange flavor.

For oral administration the compounds of the present invention may be incorporated with excipients and used in the form of non-ingestible mouthwashes and dentifrices. A mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the active ingredient may be incorporated into an antiseptic wash containing sodium borate, glycerin and potassium bicarbonate. The active ingredient also may be dispersed in dentifrices, including: gels, pastes, powders and

slurries. The active ingredient may be added in a therapeutically effective amount to a paste dentifrice that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.

5 The compositions of the present invention may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, 10 calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

One may also use solutions and/or sprays, hyposprays, aerosols and/or inhalants in the present invention for administration. Additional formulations which are suitable for other modes of administration include vaginal suppositories and/or pessaries.

15 Formulations for other types of administration that is topical include, for example, a cream, suppository, ointment or salve.

4. Dosage

20 An effective amount of the therapeutic or preventive agent is determined based on the intended goal, for example (i) inhibition of growth of a tumor or (ii) suppression of an inflammatory response at the site of disease in a subject.

The quantity to be administered, both according to number of treatments and dose, depends on the subject to be treated, the state of the subject and the protection desired. Precise amounts of the therapeutic composition also depend on the judgment of 25 the practitioner and are peculiar to each individual. For example, the frequency of application of the composition can be once a day, twice a day, once a week, twice a week, or once a month. Duration of treatment may range from one month to one year or longer. Again, the precise preventive regimen will be highly dependent on the subject, the nature of the risk factor, and the judgment of the practitioner.

30 In certain embodiments, it may be desirable to provide a continuous supply of the therapeutic compositions to the patient. For topical administrations, repeated application

would be employed. For various approaches, delayed release formulations could be used that provide limited but constant amounts of the therapeutic agent over an extended period of time. For internal application, continuous perfusion of the region of interest may be preferred. This could be accomplished by catheterization, post-operatively in some cases, followed by continuous administration of the therapeutic agent. The time period for perfusion would be selected by the clinician for the particular patient and situation, but times could range from about 1-2 hours, to 2-6 hours, to about 6-10 hours, to about 10-24 hours, to about 1-2 days, to about 1-2 weeks or longer. Generally, the dose of the therapeutic composition via continuous perfusion will be equivalent to that given by single or multiple injections, adjusted for the period of time over which the doses are administered.

5. Local and Regional Treatment

One of the prime sources of recurrent cancer is the residual, microscopic disease that remains at the primary tumor site, as well as locally and regionally, following tumor excision. In addition, there are analogous situations where natural body cavities are seeded by microscopic tumor cells. The effective treatment of such microscopic disease would present a significant advance in therapeutic regimens.

Thus, in certain embodiments, a cancer may be removed by surgical excision, creating a "cavity." Both at the time of surgery and thereafter (periodically or continuously), the therapeutic composition of the present invention is administered to the body cavity. This is, in essence, a "topical" treatment of the surface of the cavity. The volume of the composition should be sufficient to ensure that the entire surface of the cavity is contacted by the expression cassette.

C. Chemotherapeutic Agents

Certain embodiments of the present invention pertain to methods of protecting normal tissue in a subject from the toxicity associated with treatment of a disease with ionizing radiation or a chemotherapeutic agent. Other embodiments of the present invention pertain to methods of treating a disease or disorder in a subject that involve concurrently or consecutively administering a therapeutically effective amount of a

composition that includes one of the compounds of the present invention with ionizing radiation or a chemotherapeutic agent.

As used herein, "chemotherapeutic agent" is broadly defined to include a drug, toxin, compound, composition or biological entity which is used as treatment of a disease. For example, a chemotherapeutic agent can include a drug which is used in the treatment of cancer. A chemotherapeutic agent can also include a drug which is used in the treatment of another disease, including, for example, an autoimmune disease, an inflammatory disease, a neurodegenerative disease, a disease associated with ischemia and reperfusion injury, traumatic injury, atherosclerosis, aging, viral infection, and UV or ionizing radiation-induced injury and tissue damage.

Examples of chemotherapeutic agents include, but are not limited to, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, bisulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, taxol, transplatinum, 5-fluorouracil, vincristine, vinblastine and methotrexate or any analog or derivative variant thereof.

Chemotherapeutic agents can have any mechanism of action in the treatment of a disease. For example, some chemotherapeutic, directly cross-link DNA, intercalate into DNA, or lead to chromosomal and mitotic aberrations by affecting nucleic acid synthesis. Examples of agents that damage DNA include compounds that interfere with DNA replication, mitosis, and chromosomal segregation. Examples of these compounds include adriamycin (also known as doxorubicin), VP-16 (also known as etoposide), verapamil, podophyllotoxin, and the like. Widely used in clinical setting for the treatment of neoplasms, these compounds are administered through bolus injections intravenously at doses ranging from 25-75 mg/m² at 21 day intervals for adriamycin, to 35-100 mg/m² for etoposide intravenously or orally.

A further discussion of certain classes of chemotherapeutic agents used in the treatment of cancer is as follows.

1. Alkylating agents

mg/kg, peak plasma chlorambucil levels are reached within one hour and the terminal half-life of the parent drug is estimated at 1.5 hours. 0.1 to 0.2mg/kg/day or 3 to 6mg/m²/day or alternatively 0.4mg/kg may be used for antineoplastic treatment. Treatment regimes are well know to those of skill in the art and can be found in the
5 "Physicians Desk Reference" and in "Remington's Pharmaceutical Sciences" referenced herein.

Chlorambucil is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma and Hodgkin's disease. It is not curative in any of these disorders but may produce
10 clinically useful palliation. Thus, it can be used in combination with troglitazone in the treatment of cancer.

c. Cisplatin

Cisplatin has been widely used to treat cancers such as metastatic testicular or ovarian carcinoma, advanced bladder cancer, head or neck cancer, cervical cancer, lung
15 cancer or other tumors. Cisplatin can be used alone or in combination with other agents, with efficacious doses used in clinical applications of 15-20 mg/m² for 5 days every three weeks for a total of three courses. Exemplary doses may be 0.50 mg/m², 1.0mg/m², 1.50 mg/m², 1.75 mg/m², 2.0 mg/m², 3.0 mg/m², 4.0 mg/m², 5.0 mg/m², 10mg/m². Of course, all of these dosages are exemplary, and any dosage in-between these points is also
20 expected to be of use in the invention.

Cisplatin is not absorbed orally and must therefore be delivered *via* injection intravenously, subcutaneously, intratumorally or intraperitoneally.

d. Cyclophosphamide

Cyclophosphamide is 2*H*-1,3,2-Oxazaphosphorin-2-amine, *N,N*-bis(2-chloroethyl)tetrahydro-, 2-oxide, monohydrate; termed Cytosan available from Mead
25 Johnson; and Neosar available from Adria. Cyclophosphamide is prepared by condensing 3-amino-1-propanol with *N,N*-bis(2-chlorethyl) phosphoramidic dichloride [(ClCH₂CH₂)₂N--POCl₂] in dioxane solution under the catalytic influence of triethylamine. The condensation is double, involving both the hydroxyl and the amino
30 groups, thus effecting the cyclization.

Unlike other β -chloroethylamino alkylators, it does not cyclize readily to the active ethyleneimonium form until activated by hepatic enzymes. Thus, the substance is stable in the gastrointestinal tract, tolerated well and effective by the oral and parental routes and does not cause local vesication, necrosis, phlebitis or even pain.

5 Suitable doses for adults include, orally, 1 to 5 mg/kg/day (usually in combination), depending upon gastrointestinal tolerance; or 1 to 2 mg/kg/day; intravenously, initially 40 to 50 mg/kg in divided doses over a period of 2 to 5 days or 10 to 15 mg/kg every 7 to 10 days or 3 to 5 mg/kg twice a week or 1.5 to 3 mg/kg/day . A dose 250mg/kg/day may be administered as an antineoplastic. Because of
10 gastrointestinal adverse effects, the intravenous route is preferred for loading. During maintenance, a leukocyte count of 3000 to 4000/mm³ usually is desired. The drug also sometimes is administered intramuscularly, by infiltration or into body cavities. It is available in dosage forms for injection of 100, 200 and 500 mg, and tablets of 25 and 50 mg the skilled artisan is referred to "Remington's Pharmaceutical Sciences" 15th Edition,
15 chapter 61, incorporate herein as a reference, for details on doses for administration.

e. Melphalan

Melphalan, also known as alkeran, L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent which is active against selective human
20 neoplastic diseases. It is known chemically as 4-[bis(2-chloroethyl)amino]-L-phenylalanine.

Melphalan is the active L-isomer of the compound and was first synthesized in 1953 by Bergel and Stock; the D-isomer, known as medphalan, is less active against certain animal tumors, and the dose needed to produce effects on chromosomes is larger
25 than that required with the L-isomer. The racemic (DL-) form is known as merphalan or sarcolysin. Melphalan is insoluble in water and has a pK_{a1} of ~2.1. Melphalan is available in tablet form for oral administration and has been used to treat multiple myeloma.

Available evidence suggests that about one third to one half of the patients with
30 multiple myeloma show a favorable response to oral administration of the drug.

Melphalan has been used in the treatment of epithelial ovarian carcinoma. One commonly employed regimen for the treatment of ovarian carcinoma has been to administer melphalan at a dose of 0.2 mg/kg daily for five days as a single course. Courses are repeated every four to five weeks depending upon hematologic tolerance (Smith and Rutledge, 1975; Young *et al.*, 1978). Alternatively the dose of melphalan used could be as low as 0.05mg/kg/day or as high as 3mg/kg/day or any dose in between these doses or above these doses. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

2. Antimetabolites

Antimetabolites disrupt DNA and RNA synthesis. Unlike alkylating agents, they specifically influence the cell cycle during S phase. They have been used to combat chronic leukemias in addition to tumors of breast, ovary and the gastrointestinal tract. Antimetabolites include 5-fluorouracil (5-FU), cytarabine (Ara-C), fludarabine, gemcitabine, and methotrexate.

a. 5-Fluorouracil

5-Fluorouracil (5-FU) has the chemical name of 5-fluoro-2,4(1H,3H)-pyrimidinedione. Its mechanism of action is thought to be by blocking the methylation reaction of deoxyuridylic acid to thymidylic acid. Thus, 5-FU interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA). Since DNA and RNA are essential for cell division and proliferation, it is thought that the effect of 5-FU is to create a thymidine deficiency leading to cell death. Thus, the effect of 5-FU is found in cells that rapidly divide, a characteristic of metastatic cancers.

3. Antitumor Antibiotics

Antitumor antibiotics have both antimicrobial and cytotoxic activity. These drugs also interfere with DNA by chemically inhibiting enzymes and mitosis or altering cellular membranes. These agents are not phase specific so they work in all phases of the cell

cycle. Thus, they are widely used for a variety of cancers. Examples of antitumor antibiotics include bleomycin, dactinomycin, daunorubicin, doxorubicin (Adriamycin), and idarubicin, some of which are discussed in more detail below. Widely used in clinical setting for the treatment of neoplasms these compounds are administered through
5 bolus injections intravenously at doses ranging from 25-75 mg/m² at 21 day intervals for adriamycin, to 35-100 mg/m² for etoposide intravenously or orally.

a. Doxorubicin

Doxorubicin hydrochloride, 5,12-Naphthacenedione, (8*s-cis*)-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-
10 (hydroxyacetyl)-1-methoxy-hydrochloride (hydroxydaunorubicin hydrochloride, Adriamycin) is used in a wide antineoplastic spectrum. It binds to DNA and inhibits nucleic acid synthesis, inhibits mitosis and promotes chromosomal aberrations.

Administered alone, it is the drug of first choice for the treatment of thyroid adenoma and primary hepatocellular carcinoma. It is a component of 31 first-choice
15 combinations for the treatment of ovarian, endometrial and breast tumors, bronchogenic oat-cell carcinoma, non-small cell lung carcinoma, gastric adenocarcinoma, retinoblastoma, neuroblastoma, mycosis fungoides, pancreatic carcinoma, prostatic carcinoma, bladder carcinoma, myeloma, diffuse histiocytic lymphoma, Wilms' tumor, Hodgkin's disease, adrenal tumors, osteogenic sarcoma soft tissue sarcoma, Ewing's
20 sarcoma, rhabdomyosarcoma and acute lymphocytic leukemia. It is an alternative drug for the treatment of islet cell, cervical, testicular and adrenocortical cancers. It is also an immunosuppressant.

Doxorubicin is absorbed poorly and must be administered intravenously. The pharmacokinetics are multicompartmental. Distribution phases have half-lives of 12
25 minutes and 3.3 hr. The elimination half-life is about 30 hr. Forty to 50% is secreted into the bile. Most of the remainder is metabolized in the liver, partly to an active metabolite (doxorubicinol), but a few percent is excreted into the urine. In the presence of liver impairment, the dose should be reduced.

Appropriate doses are, intravenous, adult, 60 to 75 mg/m² at 21-day intervals or
30 25 to 30 mg/m² on each of 2 or 3 successive days repeated at 3- or 4-wk intervals or 20 mg/m² once a week. The lowest dose should be used in elderly patients, when there is

prior bone-marrow depression caused by prior chemotherapy or neoplastic marrow invasion, or when the drug is combined with other myelopoietic suppressant drugs. The dose should be reduced by 50% if the serum bilirubin lies between 1.2 and 3 mg/dL and by 75% if above 3 mg/dL. The lifetime total dose should not exceed 550 mg/m² in patients with normal heart function and 400 mg/m² in persons having received mediastinal irradiation. Alternatively, 30 mg/m² on each of 3 consecutive days, repeated every 4 wk. Exemplary doses may be 10 mg/m², 20 mg/m², 30 mg/m², 50 mg/m², 100 mg/m², 150 mg/m², 175 mg/m², 200 mg/m², 225 mg/m², 250 mg/m², 275 mg/m², 300 mg/m², 350 mg/m², 400 mg/m², 425 mg/m², 450 mg/m², 475 mg/m², 500 mg/m². Of course, all of these dosages are exemplary, and any dosage in-between these points is also expected to be of use in the invention.

In the present invention the inventors have employed troglitazone as an exemplary chemotherapeutic agent to synergistically enhance the antineoplastic effects of the doxorubicin in the treatment of cancers. Those of skill in the art will be able to use the invention as exemplified potentiate the effects of doxorubicin in a range of different pre-cancer and cancers.

b. Daunorubicin

Daunorubicin hydrochloride, 5,12-Naphthacenedione, (8*S-cis*)-8-acetyl-10-[(3-amino-2,3,6-trideoxy- α -L-lyxo-hexanopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-10-methoxy-, hydrochloride; also termed cerubidine and available from Wyeth. Daunorubicin intercalates into DNA, blocks DAN-directed RNA polymerase and inhibits DNA synthesis. It can prevent cell division in doses that do not interfere with nucleic acid synthesis.

In combination with other drugs it is included in the first-choice chemotherapy of acute myelocytic leukemia in adults (for induction of remission), acute lymphocytic leukemia and the acute phase of chronic myelocytic leukemia. Oral absorption is poor, and it must be given intravenously. The half-life of distribution is 45 minutes and of elimination, about 19 hr. The half-life of its active metabolite, daunorubicinol, is about 27 hr. Daunorubicin is metabolized mostly in the liver and also secreted into the bile (ca 40%). Dosage must be reduced in liver or renal insufficiencies.

Suitable doses are (base equivalent), intravenous adult, younger than 60 yr. 45 mg/m²/day (30 mg/m² for patients older than 60 yr.) for 1, 2 or 3 days every 3 or 4 wk or 0.8 mg/kg/day for 3 to 6 days every 3 or 4 wk; no more than 550 mg/m² should be given in a lifetime, except only 450 mg/m² if there has been chest irradiation; children, 25 mg/m² once a week unless the age is less than 2 yr. or the body surface less than 0.5 m, in which case the weight-based adult schedule is used. It is available in injectable dosage forms (base equivalent) 20 mg (as the base equivalent to 21.4 mg of the hydrochloride). Exemplary doses may be 10 mg/m², 20 mg/m², 30 mg/m², 50 mg/m², 100 mg/m², 150 mg/m², 175 mg/m², 200 mg/m², 225 mg/m², 250 mg/m², 275 mg/m², 300 mg/m², 350 mg/m², 400 mg/m², 425 mg/m², 450 mg/m², 475 mg/m², 500 mg/m². Of course, all of these dosages are exemplary, and any dosage in-between these points is also expected to be of use in the invention.

c. Mitomycin

Mitomycin (also known as mutamycin and/or mitomycin-C) is an antibiotic isolated from the broth of *Streptomyces caespitosus* which has been shown to have antitumor activity. The compound is heat stable, has a high melting point, and is freely soluble in organic solvents.

Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

In humans, mitomycin is rapidly cleared from the serum after intravenous administration. Time required to reduce the serum concentration by 50% after a 30 mg. bolus injection is 17 minutes. After injection of 30 mg., 20 mg., or 10 mg. I.V., the maximal serum concentrations were 2.4 mg./mL, 1.7 mg./mL, and 0.52 mg./mL, respectively. Clearance is effected primarily by metabolism in the liver, but metabolism occurs in other tissues as well. The rate of clearance is inversely proportional to the maximal serum concentration because, it is thought, of saturation of the degradative pathways. Approximately 10% of a dose of mitomycin is excreted unchanged in the urine. Since metabolic pathways are saturated at relatively low doses, the percent of a

dose excreted in urine increases with increasing dose. In children, excretion of intravenously administered mitomycin is similar.

d. Actinomycin D

Actinomycin D (Dactinomycin) [50-76-0]; $C_{62}H_{86}N_{12}O_{16}$ (1255.43) is an
5 antineoplastic drug that inhibits DNA-dependent RNA polymerase. It is a component of first-choice combinations for treatment of choriocarcinoma, embryonal rhabdomyosarcoma, testicular tumor and Wilms' tumor. Tumors that fail to respond to systemic treatment sometimes respond to local perfusion. Dactinomycin potentiates radiotherapy. It is a secondary (efferent) immunosuppressive.

10 Actinomycin D is used in combination with primary surgery, radiotherapy, and other drugs, particularly vincristine and cyclophosphamide. Antineoplastic activity has also been noted in Ewing's tumor, Kaposi's sarcoma, and soft-tissue sarcomas. Dactinomycin can be effective in women with advanced cases of choriocarcinoma. It also produces consistent responses in combination with chlorambucil and methotrexate in
15 patients with metastatic testicular carcinomas. A response may sometimes be observed in patients with Hodgkin's disease and non-Hodgkin's lymphomas. Dactinomycin has also been used to inhibit immunological responses, particularly the rejection of renal transplants.

Half of the dose is excreted intact into the bile and 10% into the urine; the half-
20 life is about 36 hr. The drug does not pass the blood-brain barrier. Actinomycin D is supplied as a lyophilized powder (0.5 mg in each vial). The usual daily dose is 10 to 15 mg/kg; this is given intravenously for 5 days; if no manifestations of toxicity are encountered, additional courses may be given at intervals of 3 to 4 weeks. Daily injections of 100 to 400 mg have been given to children for 10 to 14 days; in other
25 regimens, 3 to 6 mg/kg, for a total of 125 mg/kg, and weekly maintenance doses of 7.5 mg/kg have been used. Although it is safer to administer the drug into the tubing of an intravenous infusion, direct intravenous injections have been given, with the precaution of discarding the needle used to withdraw the drug from the vial in order to avoid subcutaneous reaction. Exemplary doses may be 100 mg/m², 150 mg/m², 175 mg/m², 200
30 mg/m², 225 mg/m², 250 mg/m², 275 mg/m², 300 mg/m², 350 mg/m², 400 mg/m², 425 mg/m², 450 mg/m², 475 mg/m², 500 mg/m². Of course, all of these dosages are

exemplary, and any dosage in-between these points is also expected to be of use in the invention.

e. Bleomycin

Bleomycin is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of *Streptomyces verticillus*. Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis.

In mice, high concentrations of bleomycin are found in the skin, lungs, kidneys, peritoneum, and lymphatics. Tumor cells of the skin and lungs have been found to have high concentrations of bleomycin in contrast to the low concentrations found in hematopoietic tissue. The low concentrations of bleomycin found in bone marrow may be related to high levels of bleomycin degradative enzymes found in that tissue.

In patients with a creatinine clearance of >35 mL per minute, the serum or plasma terminal elimination half-life of bleomycin is approximately 115 minutes. In patients with a creatinine clearance of <35 mL per minute, the plasma or serum terminal elimination half-life increases exponentially as the creatinine clearance decreases. In humans, 60% to 70% of an administered dose is recovered in the urine as active bleomycin. Bleomycin may be given by the intramuscular, intravenous, or subcutaneous routes. It is freely soluble in water.

Bleomycin should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents in squamous cell carcinoma such as head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingiva, epiglottis, larynx), skin, penis, cervix, and vulva. It has also been used in the treatment of lymphomas and testicular carcinoma.

Because of the possibility of an anaphylactoid reaction, lymphoma patients should be treated with two units or less for the first two doses. If no acute reaction occurs, then the regular dosage schedule may be followed.

Improvement of Hodgkin's Disease and testicular tumors is prompt and noted within 2 weeks. If no improvement is seen by this time, improvement is unlikely.

Squamous cell cancers respond more slowly, sometimes requiring as long as 3 weeks before any improvement is noted.

4. Corticosteroid Hormones

Corticosteroid hormones are useful in treating some types of cancer (lymphoma, leukemias, and multiple myeloma). Though these hormones have been used in the treatment of many non-cancer conditions, they are considered chemotherapy drugs when they are implemented to kill or slow the growth of cancer cells. Like troglitazone, corticosteroid hormones can increase the effectiveness of other chemotherapy agents, and consequently, they are frequently used in combination treatments. Prednisone and dexamethasone are examples of corticosteroid hormones.

5. Mitotic Inhibitors

Mitotic inhibitors include plant alkaloids and other natural agents that can inhibit either protein synthesis required for cell division or mitosis. They operate during a specific phase during the cell cycle. Mitotic inhibitors comprise docetaxel, etoposide (VP16), paclitaxel, taxol, vinblastine, vincristine, and vinorelbine.

a. Etoposide (VP16)

VP16 is also known as etoposide and is used primarily for treatment of testicular tumors, in combination with bleomycin and cisplatin, and in combination with cisplatin for small-cell carcinoma of the lung. It is also active against non-Hodgkin's lymphomas, acute nonlymphocytic leukemia, carcinoma of the breast, and Kaposi's sarcoma associated with acquired immunodeficiency syndrome (AIDS).

VP16 is available as a solution (20 mg/ml) for intravenous administration and as 50-mg, liquid-filled capsules for oral use. For small-cell carcinoma of the lung, the intravenous dose (in combination therapy) is can be as much as 100 mg/m^2 or as little as 2 mg/m^2 , routinely 35 mg/m^2 , daily for 4 days, to 50 mg/m^2 , daily for 5 days have also been used. When given orally, the dose should be doubled. Hence the doses for small cell lung carcinoma may be as high as $200\text{-}250 \text{ mg/m}^2$. The intravenous dose for testicular cancer (in combination therapy) is 50 to 100 mg/m^2 daily for 5 days, or 100 mg/m^2 on alternate days, for three doses. Cycles of therapy are usually repeated every 3

to 4 weeks. The drug should be administered slowly during a 30- to 60-minute infusion in order to avoid hypotension and bronchospasm, which are probably due to the solvents used in the formulation.

b. Taxol

5 Taxol is an antimitotic agent, isolated from the bark of the ash tree, *Taxus brevifolia*. It binds to tubulin (at a site distinct from that used by the vinca alkaloids) and promotes the assembly of microtubules. Taxol is currently being evaluated clinically; it has activity against malignant melanoma and carcinoma of the ovary. Maximal doses are 30 mg/m² per day for 5 days or 210 to 250 mg/m² given once every 3 weeks. Of course,
10 all of these dosages are exemplary, and any dosage in-between these points is also expected to be of use in the invention.

c. Vinblastine

Vinblastine is another example of a plant alkylid that can be used in combination with troglitazone for the treatment of cancer and precancer. When cells are incubated
15 with vinblastine, dissolution of the microtubules occurs.

Unpredictable absorption has been reported after oral administration of vinblastine or vincristine. At the usual clinical doses the peak concentration of each drug in plasma is approximately 0.4 mM. Vinblastine and vincristine bind to plasma proteins. They are extensively concentrated in platelets and to a lesser extent in leukocytes and
20 erythrocytes.

After intravenous injection, vinblastine has a multiphasic pattern of clearance from the plasma; after distribution, drug disappears from plasma with half-lives of approximately 1 and 20 hours. Vinblastine is metabolized in the liver to biologically activate derivative desacetylvinblastine. Approximately 15% of an administered dose is
25 detected intact in the urine, and about 10% is recovered in the feces after biliary excretion. Doses should be reduced in patients with hepatic dysfunction. At least a 50% reduction in dosage is indicated if the concentration of bilirubin in plasma is greater than 3 mg/dl (about 50 mM).

Vinblastine sulfate is available in preparations for injection. The drug is given
30 intravenously; special precautions must be taken against subcutaneous extravasation,

since this may cause painful irritation and ulceration. The drug should not be injected into an extremity with impaired circulation. After a single dose of 0.3 mg/kg of body weight, myelosuppression reaches its maximum in 7 to 10 days. If a moderate level of leukopenia (approximately 3000 cells/mm³) is not attained, the weekly dose may be increased gradually by increments of 0.05 mg/kg of body weight. In regimens designed to cure testicular cancer, vinblastine is used in doses of 0.3 mg/kg every 3 weeks irrespective of blood cell counts or toxicity.

The most important clinical use of vinblastine is with bleomycin and cisplatin in the curative therapy of metastatic testicular tumors. Beneficial responses have been reported in various lymphomas, particularly Hodgkin's disease, where significant improvement may be noted in 50 to 90% of cases. The effectiveness of vinblastine in a high proportion of lymphomas is not diminished when the disease is refractory to alkylating agents. It is also active in Kaposi's sarcoma, neuroblastoma, and Letterer-Siwe disease (histiocytosis X), as well as in carcinoma of the breast and choriocarcinoma in women.

Doses of vinblastine will be determined by the clinician according to the individual patients need. 0.1 to 0.3mg/kg can be administered or 1.5 to 2mg/m² can also be administered. Alternatively, 0.1 mg/m², 0.12 mg/m², 0.14 mg/m², 0.15 mg/m², 0.2 mg/m², 0.25 mg/m², 0.5 mg/m², 1.0 mg/m², 1.2 mg/m², 1.4 mg/m², 1.5 mg/m², 2.0 mg/m², 2.5 mg/m², 5.0 mg/m², 6 mg/m², 8 mg/m², 9 mg/m², 10 mg/m², 20 mg/m², can be given. Of course, all of these dosages are exemplary, and any dosage in-between these points is also expected to be of use in the invention.

d. Vincristine

Vincristine blocks mitosis and produces metaphase arrest. It seems likely that most of the biological activities of this drug can be explained by its ability to bind specifically to tubulin and to block the ability of protein to polymerize into microtubules. Through disruption of the microtubules of the mitotic apparatus, cell division is arrested in metaphase. The inability to segregate chromosomes correctly during mitosis presumably leads to cell death.

The relatively low toxicity of vincristine for normal marrow cells and epithelial cells make this agent unusual among anti-neoplastic drugs, and it is often included in combination with other myelosuppressive agents.

Unpredictable absorption has been reported after oral administration of
5 vinblastine or vincristine. At the usual clinical doses the peak concentration of each drug in plasma is approximately 0.4 mM.

Vinblastine and vincristine bind to plasma proteins. They are extensively concentrated in platelets and to a lesser extent in leukocytes and erythrocytes.

Vincristine has a multiphasic pattern of clearance from the plasma; the terminal
10 half-life is about 24 hours. The drug is metabolized in the liver, but no biologically active derivatives have been identified. Doses should be reduced in patients with hepatic dysfunction. At least a 50% reduction in dosage is indicated if the concentration of bilirubin in plasma is greater than 3 mg/dl (about 50 mM).

Vincristine sulfate is available as a solution (1 mg/ml) for intravenous injection.
15 Vincristine used together with corticosteroids is presently the treatment of choice to induce remissions in childhood leukemia; the optimal dosages for these drugs appear to be vincristine, intravenously, 2 mg/m² of body-surface area, weekly, and prednisone, orally, 40 mg/m², daily. Adult patients with Hodgkin's disease or non-Hodgkin's lymphomas usually receive vincristine as a part of a complex protocol. When used in the
20 MOPP regimen, the recommended dose of vincristine is 1.4 mg/m². High doses of vincristine seem to be tolerated better by children with leukemia than by adults, who may experience severe neurological toxicity. Administration of the drug more frequently than every 7 days or at higher doses seems to increase the toxic manifestations without proportional improvement in the response rate. Precautions should also be used to avoid
25 extravasation during intravenous administration of vincristine. Vincristine (and vinblastine) can be infused into the arterial blood supply of tumors in doses several times larger than those that can be administered intravenously with comparable toxicity.

Vincristine has been effective in Hodgkin's disease and other lymphomas. Although it appears to be somewhat less beneficial than vinblastine when used alone in
30 Hodgkin's disease, when used with mechlorethamine, prednisone, and procarbazine (the so-called MOPP regimen), it is the preferred treatment for the advanced stages (III and

IV) of this disease. In non-Hodgkin's lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin, and prednisone. Vincristine is more useful than vinblastine in lymphocytic leukemia. Beneficial response have been reported in patients with a variety of other neoplasms, particularly Wilms' tumor, neuroblastoma, brain tumors, rhabdomyosarcoma, and carcinomas of the breast, bladder, and the male and female reproductive systems.

Doses of vincristine for use will be determined by the clinician according to the individual patients need. 0.01 to 0.03mg/kg or 0.4 to 1.4mg/m² can be administered or 1.5 to 2mg/m² can also be administered. Alternatively 0.02 mg/m², 0.05 mg/m², 0.06 mg/m², 0.07 mg/m², 0.08 mg/m², 0.1 mg/m², 0.12 mg/m², 0.14 mg/m², 0.15 mg/m², 0.2 mg/m², 0.25mg/m² can be given as a constant intravenous infusion. Of course, all of these dosages are exemplary, and any dosage in-between these points is also expected to be of use in the invention.


6. Nitrosoureas

Nitrosoureas, like alkylating agents, inhibit DNA repair proteins. They are used to treat non-Hodgkin's lymphomas, multiple myeloma, malignant melanoma, in addition to brain tumors. Examples include carmustine and lomustine.

a. Carmustine

Carmustine (sterile carmustine) is one of the nitrosoureas used in the treatment of certain neoplastic diseases. It is 1,3bis (2-chloroethyl)-1-nitrosourea. It is lyophilized pale yellow flakes or congealed mass with a molecular weight of 214.06. It is highly soluble in alcohol and lipids, and poorly soluble in water. Carmustine is administered by intravenous infusion after reconstitution as recommended. The structural formula is:

Sterile carmustine is commonly available in 100 mg single dose vials of lyophilized material.



Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

5 Carmustine is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in brain tumors such as glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. Also it has been used in combination with prednisone to treat multiple myeloma. Carmustine has proved useful, in the treatment of Hodgkin's Disease
10 and in non-Hodgkin's lymphomas, as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

The recommended dose of carmustine as a single agent in previously untreated patients is 150 to 200 mg/m² intravenously every 6 weeks. This may be given as a single
15 dose or divided into daily injections such as 75 to 100 mg/m² on 2 successive days. When carmustine is used in combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, the doses should be adjusted accordingly. Doses subsequent to the initial dose should be adjusted according to the hematologic response of the patient to the preceding dose. It is of course understood that other doses
20 may be used in the present invention for example 10mg/m², 20mg/m², 30mg/m² 40mg/m² 50mg/m² 60mg/m² 70mg/m² 80mg/m² 90mg/m² 100mg/m² . The skilled artisan is directed to, "Remington's Pharmaceutical Sciences" 15th Edition, chapter 61. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the
25 appropriate dose for the individual subject.

b. Lomustine

Lomustine is one of the nitrosoureas used in the treatment of certain neoplastic diseases. It is 1-(2-chloro-ethyl)-3-cyclohexyl-1 nitrosourea. It is a yellow powder with the empirical formula of C₉H₁₆ClN₃O₂ and a molecular weight of 233.71. Lomustine is
30 soluble in 10% ethanol (0.05 mg per mL) and in absolute alcohol (70 mg per mL). Lomustine is relatively insoluble in water (<0.05 mg per mL). It is relatively unionized

at a physiological pH. Inactive ingredients in lomustine capsules are: magnesium stearate and mannitol.

Although it is generally agreed that lomustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit
5 several key enzymatic processes by carbamylation of amino acids in proteins.

Lomustine may be given orally. Following oral administration of radioactive lomustine at doses ranging from 30 mg/m² to 100 mg/m², about half of the radioactivity given was excreted in the form of degradation products within 24 hours. The serum half-
10 life of the metabolites ranges from 16 hours to 2 days. Tissue levels are comparable to plasma levels at 15 minutes after intravenous administration.

Lomustine has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in both primary and metastatic brain tumors, in patients who
15 have already received appropriate surgical and/or radiotherapeutic procedures. It has also proved effective in secondary therapy against Hodgkin's Disease in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

The recommended dose of lomustine in adults and children as a single agent in
20 previously untreated patients is 130 mg/m² as a single oral dose every 6 weeks. In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m² every 6 weeks. When lomustine is used in combination with other myelosuppressive drugs, the doses should be adjusted accordingly. It is understood that other doses may be used for example, 20mg/m² 30mg/m², 40 mg/m², 50mg/m², 60mg/m²,
25 70mg/m², 80mg/m², 90mg/m², 100mg/m², 120mg/m² or any doses between these figures as determined by the clinician to be necessary for the individual being treated.

7. Miscellaneous Agents

Some chemotherapy agents do not qualify into the previous categories based on their activities. However, it is contemplated that they are included within the method of
30 the present invention for use in combination therapies of cancer with troglitazone. They

include amsacrine, L-asparaginase, tretinoin, and Tumor Necrosis Factor (TNF), some of which are discussed below.

a. Tumor Necrosis Factor

5 Tumor Necrosis Factor [TNF; Cachectin] is a glycoprotein that kills some kinds of cancer cells, activates cytokine production, activates macrophages and endothelial cells, promotes the production of collagen and collagenases, is an inflammatory mediator and also a mediator of septic shock, and promotes catabolism, fever and sleep. Some infectious agents cause tumor regression through the stimulation of TNF production. TNF can be quite toxic when used alone in effective doses, so that the optimal regimens
10 probably will use it in lower doses in combination with other drugs. Its immunosuppressive actions are potentiated by gamma-interferon, so that the combination potentially is dangerous. A hybrid of TNF and interferon- α also has been found to possess anti-cancer activity.

In addition to combination treatment therapies comprising troglitazone or
15 thiazolidinediones and another chemotherapeutic agent, it is also contemplated that the present invention includes the use of sex hormones according to the methods described herein in the treatment of cancer. While this method is not limited to the treatment of a specific cancer, this use of hormones in this combination therapy has benefits with respect to cancers of the breast, prostate, and endometrial (lining of the uterus).
20 Examples of these hormones are estrogens, anti-estrogens, progesterones, and androgens.

D. UV and Ionizing Radiation

Certain embodiments of the present invention pertain to methods of protecting normal tissue in a subject from the toxicity associated with treatment of a disease with ionizing radiation. Other embodiments of the present invention pertain to methods of
25 methods of treating a disease that involve concurrently or consecutively administering a therapeutically effective amount of a compound of the present invention and ionizing radiation.

UV-radiation is defined herein to include radiation that induces DNA damage by UV waves. Ionizing radiation is defined herein to include radiation and waves that
30 induce DNA damage through the use of, for example, γ -irradiation, radioisotopes, and the

like. UV-radiation and ionizing radiation are commonly used in the therapy of disease, such as cancer. Therapy may be achieved by irradiating the localized tumor site with the above described forms of radiation. It is most likely that all of these factors effect a broad range of damage DNA, on the precursors of DNA, the replication and repair of DNA, and the assembly and maintenance of chromosomes. As used herein, treatment with UV-radiation and ionizing radiation is not limited to cancer, but can include treatment of other diseases. One of ordinary skill in the art would be familiar with the clinical indications for use of these forms of radiation.

One of ordinary skill in the art would be familiar with the dosage range of UV or ionizing radiation that are required in the treatment of a particular disease process, such as cancer. Dosage ranges for ionizing radiation that uses radioisotopes may vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

E. Other Secondary Therapies

Certain embodiments of the present invention pertain to methods of treating a disease or disorder in a subject that include concurrently or consecutively administering a therapeutically effective amount of the composition and ionizing radiation or a chemotherapeutic agent to the subject. Ionizing radiation and chemotherapeutic agents have been previously discussed. Concurrent and consecutive administration have also been previously discussed.

The subject, as noted above, can be afflicted with any disease or disorder. One of ordinary skill in the art would be familiar with the wide range of diseases and disorders that are amenable to treatment with a chemotherapeutic agent or ionizing radiation. For example, the subject may be a cancer patient.

In certain embodiments of the present methods, the subject who is to receive the therapeutic composition of the present invention may not only receive treatment with ionizing radiation or a chemotherapeutic agent, but may also be receiving treatment with another modality. For example, if the patient is a cancer patient, the patient may be receiving treatment with surgery or gene therapy.

Surgical treatment for removal of an abnormal growth, such as a cancer, is a common therapeutic method. This attempts to remove the entire abnormal growth. In

the case of cancer, surgery is generally combined with chemotherapy and/or radiotherapy to ensure the destruction of any remaining neoplastic or malignant cells. Thus, in the context of the present invention surgery may be used in addition to using the therapeutic compositions, chemotherapy, and ionizing radiation of the present invention.

5 In the case of surgical intervention, the compositions of the present invention may be used preoperatively, to render an inoperable tumor subject to resection. Alternatively, the present invention may be used at the time of surgery, and/or thereafter, to treat residual or metastatic disease. For example, a resected tumor bed may be injected or perfused with a formulation comprising a the therapeutic composition. The perfusion
10 may be continued post-resection, for example, by leaving a catheter implanted at the site of the surgery. Periodic post-surgical treatment also is envisioned.

 In certain embodiments, the tumor being treated may not, at least initially, be resectable. Treatments with therapeutic viral constructs may increase the resectability of the tumor due to shrinkage at the margins or by elimination of certain particularly
15 invasive portions. Following treatments, resection may be possible. Additional treatments subsequent to resection will serve to eliminate microscopic residual disease at the tumor site.

 A typical course of treatment, for a primary tumor or a post-excision tumor bed, will involve multiple doses. Typical primary tumor treatment involves a 6 dose
20 application over a two-week period. The two-week regimen may be repeated one, two, three, four, five, six or more times. During a course of treatment, the need to complete the planned dosings may be re-evaluated.

 The treatments may include various "unit doses." Unit dose is defined as containing a predetermined-quantity of the therapeutic composition. The quantity to be
25 administered, and the particular route and formulation, are within the skill of those in the clinical arts. A unit dose need not be administered as a single injection but may comprise continuous infusion over a set period of time. Unit dose of the present invention may conveniently may be described in terms of plaque forming units (pfu) for a viral construct. Unit doses range from 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , 10^{12} , 10^{13}
30 pfu and higher.

Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. Methods of the present invention may involve treatment of subjects who are concurrently receiving immunotherapy for a disease.

5 Immunotherapy, thus, could be used as part of a combined therapy, in conjunction with therapy using the compositions of the present invention.

Secondary treatments may also include gene therapy. One of ordinary skill in the art would be familiar with treatment options involving gene therapy.

10 Examples of other types of therapies include, cryotherapy, toxin therapy, or hormonal therapy. One of skill in the art would know that this list is not exhaustive of the types of treatment modalities available for diseases, such as cancer.

F. Protection of Normal Tissue from Toxicity of Ionizing Radiation and Chemotherapy

15 As noted above, certain embodiments of the present invention pertain to methods of protecting normal tissue in a subject from the toxicity associated with treatment of a disease with ionizing radiation or a chemotherapeutic agent, involving concurrently or consecutively administering to the subject a prophylactically effective amount of the composition and the ionizing radiation or chemotherapeutic agent.

20 Concurrent and consecutive administration have been discussed and defined above. One of ordinary skill in the art would be familiar with methods of administration and dosing for optimizing protection of normal tissue from the toxicity associated with ionizing radiation and chemotherapy. The dose and method of administration will in large part be related to the particular disease process, and to the required course of ionizing radiation or chemotherapy that is necessary to treat the disease. In some
25 embodiments, a single dose of the composition will be sufficient, whereas in other embodiments, a course of the composition involving multiple doses over a prolonged period of time may be required.

For example, in some embodiments, administration of the prophylactic composition may be conducted such that it is complete within about 5 minutes, about 10
30 minutes, about 30 minutes, about 1 hour, or about 6 hours prior to initiation of a dose of radiation therapy or chemotherapy. In other embodiments, the prophylactically effective

amount of the composition is administered concurrently with the ionizing radiation or chemotherapeutic agent. One of ordinary skill in the art would be able to design an appropriate regimen involving the composition such that it would be most effective in preventing the toxicity associated with treatment of a disease with ionizing radiation or a chemotherapeutic agent.

G. Examples

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1

D609 is a Potent Antioxidant

D609 is a xanthate derivative that can reversibly dissociate and protonate in solution to form xanthate anions and xanthic acid, respectively (Rao, 1971). In a cell free condition, D609 can inhibit several hydroxyl radical-induced events, including (1) oxidation of DHR and terephthalic acid; (2) formation of the PBN-free radical spin adducts; and (3) lipid peroxidation of synaptosomal membranes.

The known reactive oxygen species (ROS) that D609 can scavenge include HO^\cdot , O_2^\cdot , and H_2O_2 (Giron-Calle *et al.*, 2002). D609 has the ability to react with other ROS and free radicals, since xanthates generally have a high reduction potential (Rao, 1971). Using cyclic voltammetry, a convenient tool for the evaluation of the antioxidant capacity of various small molecules and biological specimens (Chevion *et al.*, 1997), the reducing power of D609 at physiological pH was measured. D609 was dissolved in PBS (pH 7.4) at 2 mM concentration, and $E_{1/2}$ was measured using a cyclic voltammetry apparatus (Model CV-2, from BAS, West Lafayette, IN). As shown in FIG. 3, D609 can donate a single electron at the potential of $E_{1/2} = 350 \text{ mV}$. The $E_{1/2}$ value of D609 is similar to that

of vitamin C ($E_{1/2} = 380$ mV) (Chevion *et al.*, 1997). These findings demonstrate that D609 is a novel biological antioxidant.

EXAMPLE 2

D609-Mediated Radiation Protection

5 It has been shown that various nucleophilic sulfur antioxidants are potent cytoprotectants that can ameliorate IR-induced oxidative stress and tissue damage. Thus, whether D609 also functions as an effective radioprotectant was investigated.

BALB/c mice were exposed to 6.5 or 8.5 Gy total body IR 10 minutes after they received a single dose (50 mg/kg) of iv injection of D609 or vehicle (saline) through the
10 tail vein. The death of these mice was recorded during a 30-day observation period after IR.

It was found that pre-incubation of lymphocytes with D609 resulted in a significant diminution of several IR-induced events, including: 1) production of ROS; 2) decrease in intracellular reduced GSH; 3) oxidative damage to proteins and lipids; and 4)
15 activation of NF- κ B. Moreover, when D609 (50 mg/kg, iv) was administered to mice 10 min prior to total body IR, it protected the mice from IR-induced lethality (FIG. 4A, FIG. 4B). However, incubation of various tumor cells with D609 failed to protect them from IR-induced apoptosis. Instead, D609 exhibited selective cytotoxicity against these cells and enhanced IR-induced tumor cell apoptosis. These results indicate that D609 is not
20 only a potent antioxidant but also functions as an effective cytoprotectant that has the ability to selectively inhibit IR-induced normal cell oxidative damage and protect mice from IR-induced lethality.

EXAMPLE 3

D609 is a Selective Antitumor Agent but a Normal Immune Response Enhancer

25

Unlike other nucleophilic sulfur antioxidants, D609 is also a potent and selective antitumor agent. Previously, it was shown that D609 kills transformed and malignant cells but has little, if any, toxicity against normal cells *in vitro* and *in vivo*. Studies were conducted to determine whether D609 selectively induces tumor cell death by apoptosis.

The cell viability was analyzed by MTT assay after various leukemia cells (U937, Jurkat, SupT13 and A20), solid tumor cells (HT1080) and normal human fibroblasts (WI38) were cultured with vehicle or different concentrations of D609 for 48 hours. The results, shown in FIG. 5A and FIG. 5B, are expressed as a percent of vehicle control and presented as means \pm SEM (n = 3).

As shown in FIG. 5, both leukemia and solid tumor cells incubated with D609 exhibited a dose-dependent reduction in cell viability, while normal human fibroblasts (WI38) were relatively resistant to D609 treatment (FIG. 5A, FIG. 5B). Using the annexin V-FITC staining and flow cytometric analysis, it was found that D609 primarily induces tumor cell death by apoptosis. This was also confirmed by the analysis of sub-G_{0/1} cells, which measures D609-induced DNA fragmentation. In addition, when D609 was combined with daunorubicin, mitoxantrone, TNF α , or ant-Fas antibody, it enhanced their tumor cell cytotoxicity (Amtmann and Sauer, 1990; Bettaieb *et al.*, 1999; Pron-Ares *et al.*, 1997).

Studies were conducted to determine whether D609 enhances mouse splenic lymphocyte mitogenic responses and IFN γ production. Mouse splenic lymphocytes at 2.5×10^6 /ml were stimulated with LPS or ConA in the presence or absence of D609. The cell proliferation was measured by ³H-thymidine incorporation after the cells were cultured with LPS (FIG. 6A) or with ConA (FIG. 6B). Similar results on D609-induced enhancement of lymphocyte proliferation also were observed in cells stimulated either lower or higher concentrations of LPS or ConA. In addition, the supernatants of ConA-stimulated lymphocyte cultures were harvested at various times and measured for IFN γ production by ELISA (FIG. 6C).

As shown in FIG. 6A-FIG. 6C, D609 actually enhanced normal lymphocyte proliferation in response to mitogen stimulation. As shown in Fig. 6, incubation of normal mouse splenic lymphocytes with D609 (188 μ M = 50 μ g/ml) enhanced their mitogenic responses to stimulation with LPS (a B cell mitogen) or ConA (a T cell mitogen). The enhancement was seen in the cells stimulated with various concentrations of LPS (from 0.75 to 10 μ g/ml) or ConA (from 0.3 to 10 μ g/ml). The greatest enhancement was seen in the cells that were stimulated with a sub-optimal concentration of LPS (2.5 μ g/ml) or ConA (1.25 μ g/ml) (FIG. 6A, FIG. 6B). In addition, the production

of various cytokines, particularly interferon- γ (IFN γ), was significantly augmented by D609 (Fig. 6C). These results suggest that D609 not only acts as selective tumor cytotoxic agent but also may function as an immune modulator that enhances lymphocyte-mediated immune reactions. Considering that IFN γ is one of the major
5 cytokines regulating T and NK cell-mediated antitumor activities, D609 may have the potential to enhance antitumor immune responses.

EXAMPLE 4

Mechanisms of Antitumor Action of D609

To determine if inhibition of PC-PLC or SMS is responsible for D609 antitumor
10 action, studies were conducted to compare the inhibitory effects of D609, cyclohexyl xanthate and tricyclodecanol on PC-PLC and SMS and the relationship of this inhibition to tumor cytotoxicity.

In this study, p-nitrophenyl-phosphorylcholine (pNPP, 40 mM) was incubated with 2 U/ml phospholipase C (Type XI from *B. cereus*) in the presence or absence of
15 various concentrations of inhibitors for 2 hrs at 37°C. The amount of the cleaved substrate pNPP was quantified by determination of the optical density at 410 nm using an ELISA reader. The results are expressed as percent of vehicle control and presented as means \pm SEM (n=3) (FIG. 7A). NBD-C₆-ceramide and PC were incubated with U937 cell lysates containing 50 μ g protein in the presence or absence of various concentrations
20 of inhibitors for 30 min at 30°C. The formation of NBD-C₆-sphingomyelin as analyzed by TLC and quantified by determination of the fluorescent intensity of NBD-C₆-sphingomyelin using a phosphoimager. The results are expressed as percent of vehicle control (FIG. 7B). U937 cells were incubated with different concentrations of inhibitors for 48 hours. The cell viability was analyzed by MTT assay and the results are expressed
25 as percent of vehicle control and presented as means \pm SEM (n = 3) (FIG. 7C).

As shown in FIG. 7, both D609 and cyclohexyl xanthate dose-dependently inhibited the activity of the *Bacillus cereus* bacteria-derived PC-PLC as described previously (FIG. 7A; Amtmann, 1996). Using a cell lysate-based *in vitro* assay system (Luberto and Hannun, 1998; Riboni *et al.*, 2001), it was found that only D609 inhibited
30 the SMS activity in a dose-dependent manner, while cyclohexyl xanthate had no effect

(FIG. 7B). Tricyclodecanol, the alcohol used to synthesize D609, is devoid of any of these activities (FIG. 7A, FIG. 7B). When U937 cells were incubated with different concentrations of these compounds, it was found that only D609 induced significant cell death in U937 cells in a dose-dependent manner whereas the other two compounds had no or only modest effects on the cell viability. These results suggest that D609 may induce tumor cell death primarily by inhibiting SMS activity.

To validate if inhibition of SMS may mediate D609-induced tumor cell death, the cellular level of SMS activity in U937 cells treated with vehicle or D609 were studied. Cell lysates were prepared after U937 cells were cultured with vehicle or different concentrations of D609 for 2 hrs when the cell death was undetectable (FIG. 8A). NBD-C₆-ceramide and PC were incubated with the cell lysates containing 50 μ g proteins for 30 min at 30°C. The formation of NBD-C₆-sphingomyelin was analyzed by TLC and quantified by determination of the fluorescent intensity of NBD-C₆-sphingomyelin using a phosphoimager. The results, shown in FIGS. 8B-8D, are expressed as percent of the control cultures with vehicle and presented as means \pm SEM (n = 3). Lipids were extracted from U937 cells after the cells were cultured with vehicle or different concentrations of D609 for 2 hrs. The levels of ceramide (FIG. 8B) and DAG (FIG. 8C) were analyzed by the DAG kinase assay, normalized to the levels of cellular phospholipid and expressed as pmole/nmole phosphate (pi) or the ratio of ceramide and DAG (FIG. 8D). The results represent means \pm SEM (n = 3).

As shown in FIG. 8A, U937 cells incubated with different concentrations of D609 exhibited a dose-dependent reduction in SMS activity. The IC₅₀ value is about 90 μ M (or 23.8 μ g/ml). Since SMS transfers the PhoCho group from PC to ceramide, generating DAG and SM, SMS has the ability of simultaneously regulating the intracellular levels of DAG and ceramide in opposite directions (Luberto and Hannun, 1998). Inhibition of SMS by D609 should increase the intracellular level of ceramide while decreasing that of DAG, which could result in an elevation of the ratio between these two important intracellular signal molecules that regulate cell proliferation or cell cycle arrest and senescence, survival and cell death. Indeed, as shown in FIGS. 8B-8D, U937 cells treated with different concentrations of D609 showed an increase in the level of ceramide

and a decrease in that of DAG in a dose-dependent manner. Correspondingly, the ratio between ceramide and DAG was dramatically elevated.

It is well known that ceramide functions as a negative cell regulator that can induce cell cycle arrest, senescence or apoptosis. In contrast, DAG stimulates cell proliferation and promotes cell survival, primarily via activation of PKC. To determine if the changes in the levels of ceramide and DAG resulting from SMS inhibition contribute to D609-induced apoptosis in U937 cells, the cells were incubated with vehicle, H7 (a PKC inhibitor), ceramide, or H7 plus ceramide. U937 cells ($1 \times 10^6/\text{ml}$) were incubated with 5 μM C6-ceramide and 25 μM H7 alone or combination for 24 hr at 37 °C. Apoptosis of the cells was measured by Annexin V-FITC staining and flow cytometry and expressed as percent of Annexin V positive cells. a, $p < 0.05$ vs Control; b, $p < 0.05$ vs H7- or C6-treated cells (FIG. 9).

It was found that both H7 and ceramide induced U937 cell apoptosis in a dose-dependent manner. When the cells were incubated with a low dose of H7 (25 μM) or ceramide (5 μM), the induction of apoptosis was modest by either agent (FIG. 9). However, the combined treatment with the same low doses of H7 and ceramide resulted in a synergistic induction of apoptosis (FIG. 9).

Furthermore, when U937 cells were treated with PMA (an activator of PKC) prior to their exposure to D609, PMA partially attenuated D609-induced apoptosis in these cells (FIG. 10). In these experiments, U937 cells were pre-incubated with PMA (25 nM) for 30 min and then were cultured with vehicle or D609 (150 μM) for 24 hrs. Apoptotic cells were analyzed by Annexin V-FITC staining and flow cytometry and the results are expressed as means \pm SEM ($n = 3$). a, $p < 0.001$ vs control without PMA; b, $p < 0.05$ vs D609 treatment alone (FIG. 10).

These results indicate that D609-induces tumor cell apoptosis primarily via inhibition of SMS, which results in an increase in the level of ceramide and a decrease in the level of DAG in favor of apoptosis induction.

EXAMPLE 5

Disparity of *in vitro* and *in vivo* Antitumor Effects of D609

Although D609 is a selective antitumor agent and exhibits potent cytotoxicity against a variety of tumor cells *in vitro*, it lacks significant therapeutic efficacy against cancer *in vivo*.

Studies were conducted to evaluate the effects of D609 and/or IR on A20 cell viability and growth *in vitro*. The cell viability was analyzed by MTT assay after A20 cells were cultured with vehicle or different concentrations of D609 for 48 hrs. The results, shown in FIG. 11A, are expressed as percent of vehicle control. A20 cells were untreated (Control), irradiated (IR 4 Gy), incubated with D609 alone, or treated with both D609 and IR. The cell viability and/or proliferation were measured by MTT assay at different times after the cells were placed into well of 96-well plate (2×10^4 /0.2 ml/well). The results are expressed as means \pm SEM (n = 3) (FIG. 11B).

The results show that D609 exhibits high cytotoxicity against A20 cells (a murine B cell lymphoma cells) *in vitro*. The LD₅₀ value of D609 against A20 cells is about 106 μ M or 28.2 μ g/ml (FIG. 11A). A20 cells are also sensitive to IR-induced cell death. However, treatment of A20 cells with D609 did not protect the cell from IR, instead, it enhanced their response to IR. Particularly, on day 5 after exposure to IR, a few of the IR resistant cells started to grow back in cultures treated with IR alone, while cell proliferation was further suppressed in cultures treated with D609 alone or in combination with IR (FIG. 11B).

Studies were then conducted to determine whether there were therapeutic effects of D609 and/or IR on A20 lymphoma *in vivo*. A20 lymphoma was induced in normal BALB/c male mice by the tail vein injection of 5×10^5 cultured A20 cells. Two days later, the mice were assigned to groups of 10 mice each and received i.v. 1) saline, 2) 50 mg/kg D609, 3) saline plus 6.0 Gy irradiation or 4) D609 plus irradiation. Total body irradiation was given 10 min after D609 injection. Survival of each mouse was then followed by daily monitoring and weighing (5x/week).

However, mice inoculated with A20 cells exhibited no significant therapeutic response to either D609 or IR or treatment with both (FIG. 12). Similar results showing a lack of therapeutic efficacy for D609 have been reported for other types of mouse and

human xenograft tumor models, including mouse Lewis lung cancer (Amtmann and Sauer, 1990; Schick *et al.*, 1989; Sauer *et al.*, 1990). These results indicate that the disparity between the *in vitro* and *in vivo* antitumor activities of D609 may reflect its poor pharmacokinetics due to the rapid metabolism of D609. This rapid metabolism may result in low levels of D609 reaching the target tumor.

EXAMPLE 6

Rational Design and Synthesis of Prodrug Forms of D609

This example pertains to the synthesis of two series of D609 prodrugs: an S-(alkoxyphosphoryl)- and an S-(alkoxylacyl)-D609 series. The following is a summary of the approaches used to synthesize the phosphoryl analog designated compound 7 in FIG. 13 and the acyl analogs designated compound 22 and compound 26 in FIG. 14.

Synthesis of the alkoxyphosphoryl prodrug: The synthesis scheme for the alkoxyphosphoryl prodrug designated compound 7 in FIG. 13 was developed based on the work of Krise *et al.*, 1999, which is specifically herein incorporated by reference, and is shown in the scheme shown in FIG. 13. Briefly the (chloromethoxy), di(^tbutoxy) phosphate was synthesized according to the procedure of Krise *et al.*, 1999, and reacted with the potassium salt of D609 in acetonitrile. The reaction occurred rapidly and generated the desired S-(methylenoxy), di(^tbutoxy) phosphoryl D609 (compound 7) in 65 % yield, after purification by silica gel chromatography.

Synthesis of the alkoxyacyl prodrugs (R= ^tBu and CH₃): The syntheses of the alkoxyacyl prodrugs designated compound 22 and compound 26 in FIG. 14 were developed based on the work of Nudelman *et al.*, 2001, and are shown in FIG. 14. Chloromethyl acetate (compound 17 in FIG. 14) was synthesized according to the procedure of Rasmussen and Leonard, 1967, which is herein specifically incorporated by reference. Reaction of this alkylating agent with the potassium salt of D609 generated the desired methyleneoxyacetyl D609 (compound 22 in FIG. 14) which was isolated by column chromatography in 64 % yield. The synthesis of the desired methyleneoxypivalolyl D609 (compound 26 in FIG. 14) was accomplished by the same procedure, beginning with the commercially available chloromethyl pivalate. The yield of compound 26 after column chromatography was 53 %.

Stability and hydrolytic property of D609 prodrugs: An HPLC assay was developed to examine the stability of D609 and the newly synthesized D609 prodrugs. It was found that D609 underwent rapid oxidation in saline solution at room temperature with a $T_{1/2}$ about 19.5 min. The rate of oxidation was accelerated even further by the addition of low concentrations of mild oxidants, such as H_2O_2 . Compared to D609, the D609 prodrugs, S-(methylenoxy, di(tbutoxy) phosphoryl D609 (compound 7 in FIG. 13) and S-methylenoxyacetyl D609 (compound 22 in FIG. 14), are highly stable as no spontaneous oxidation or hydrolysis of these compounds was detected during a 48-hour incubation at room temperature.

Compound 7 and compound 22 are designed to release D609 in two steps: a) phosphatase-, esterase-, or amidase-catalyzed hydrolysis of the phosphate ester and acyl ester bond (K_1), respectively; followed by b) rapid conversion of the resulting hydroxymethyl D609 to formaldehyde and D609 (K_2) (FIG. 15). Since the second step of the reactions is so facile, the pseudo-first-order rate constant of the overall reaction rate (k_{obs}) mainly reflects the rate for the first step (K_1) of the enzyme-catalyzed reactions.

To determine the hydrolytic property of compound 22, this compound (333 μ M in 50 mM Tris-HCl buffer with 15% DMSO, pH 8.0) was incubated with 2.98 U/ml porcine liver esterase (PLE, EC 3.1.1.1, from Sigma) at 37°C (Wang *et al.*, 1998). The release of D609 was determined at different times by measuring the colorimetric reaction of D609 with DTNB (200 μ M), whereas the hydrolysis of the prodrug was monitored by measuring the disappearance of compound 22 by HPLC. The endpoint of the enzyme-catalyzed reaction was obtained within 150 min, when 99% of the prodrug was hydrolyzed. A pseudo-first-order plot for the hydrolysis of the prodrug was constructed from the logarithm of remaining ester versus time. The pseudo-first-order rate constant (k_{obs}) and $T_{1/2}$ ($= 0.693/ k_{obs}$) were calculated based on the slope of the linear curve (Wang *et al.*, 1998). The k_{obs} for compound 22 was $15.42 \times 10^{-3}/\text{min}$ and $T_{1/2}$ was 44.95 min. The complete hydrolysis of the prodrug by esterase led to near-quantitative 85% molar recovery of D609 from the prodrug. The 15% not recovered may represent the rapid oxidation of D609 after its release. Similarly, compound 7 (222 μ M) was completely hydrolyzed by alkaline phosphatase (3.125 U/ml, EC 3.1.3.1, from Sigma) in a glycine buffer solution (1mM $ZnCl_2$, 1mM $MgCl_2$, and 0.1 M glycine, pH 9.0) at 37°C

within 60 min (Krise *et al.*, 1999). The k_{obs} for compound 22 was $52.54 \times 10^{-3}/\text{min}$ and $T_{1/2}$ was 13.19 min. These findings demonstrate that these D609 prodrugs have the appropriate hydrolytic properties and will be advanced for *in vivo* testing as proposed in our research plan.

5

EXAMPLE 7

D609 Prodrugs: Synthesis and Analytical Data

S-(Methyleneoxyacetyl) D609, (compound 22 in FIG. 16A): Chloromethyl acetate was prepared according to the method of Nudelman *et al.*, 2001: a mixture of acetyl chloride (5.00 g, 64 mmol), paraformaldehyde (1.91g, 64 mmol) and ZnCl_2 (cat.) were mixed
10 together at room temperature. An exothermic reaction occurred after several minutes, whereupon the temperature reached 75-80° C. After the exotherm was completed, the reaction was heated to 75° C for 3 hrs. The product was isolated by distillation (90-90.5°C, 760 mmHg) to give the product as a colorless oil (1.96 g, 29 %). The chloromethyl acetate (0.04g, 0.38 mmol) was added to a solution of D609 (100 mg, 0.38
15 mmol) in anhydrous acetonitrile (15 ml) maintained under nitrogen. The reaction was stirred at room temperature for 16 hrs. The mixture was then placed under reduced pressure to remove the solvent and the residue was extracted three times with 10 ml of dichloromethane. The organic solutions were combined and the solvent evaporated. The residue was separated by column chromatography over silica gel (ethyl acetate: hexane=
20 1:15) to give the target compound as a yellow color oil. (0.070g, 63.6% yield)
Data (compound 22): $^1\text{H-NMR}$ (CDCl_3 , 400MHz, δppm): 5.59 (s, 2H), 5.47(m, 1H), 2.46-1.46 (m, 14H), 2.06 (s, 3H, CH_3). $^{13}\text{C-NMR}$ (CDCl_3 , 100MHz, δppm): 21.15, 26.60, 27.44, 28.60, 34.12, 40.60, 41.08, 44.17, 44.43, 47.04, 66.74, 85.85, 170.50, 210.10.

S-(Methyleneoxy-(2,2-dimethylpropionyl)) D609, (compound 26 in FIG. 16B): The
25 synthesis of 26 was performed as described for 7. Chromatography over silica gel (ethyl acetate: hexane= 1:25) gave the desired product as a yellow oil (0.030 g, 52.6 % yield).
Data (26): $^1\text{H-NMR}$ (CDCl_3 , 400MHz, δppm):5.56 (s, 2H), 5.21 (m, 1H), 2.26-0.85 (m, 14H), 1.17 (s, 9H); $^{13}\text{C-NMR}$ (CDCl_3 , 100MHz, δppm): 27.24, 28.04, 30.14, 31.93, 32.25, 39.09, 39.30, 39.92, 42.75, 46.12, 47.50, 66.61, 87.87, 179.0, 210.10.

S-(Methyleneoxy)-D609, di(^tbutoxy) phosphate, (compound 7 in FIG. 16C): Di-tert-butyl chloromethyl phosphate was prepared as described by Krise *et al.*, 1999. Di-tert-butyl chloromethyl phosphate (97mg, 0.38mmol) was dissolved in acetonitrile (5 ml) and a solution of D609 (100mg, 0.38mmol) in acetonitrile (15 ml) was added, while being
5 maintained under nitrogen. The reaction was stirred at room temperature for 12 hrs. The mixture was then placed under reduced pressure to remove solvent. The residue was then extracted three times with 10 ml of dichloromethane. The organic solutions were combined and the solvent evaporated to give the crude product. The residue was separate by column chromatography over silica gel (ethyl acetate: hexane= 1:5) to give the target
10 compound 7 as a yellow oil (0.110 g, 64.7 %) Data (compound 7): ¹H-NMR (CDCl₃, 400MHz, δppm) 5.59 (m, 1H), 5.42(d, 2H), 2.45-1.54(m, 14H), 1.40(s, 18H); ¹³C-NMR (CDCl₃, 100MHz, δppm) 26.00, 27.00, 28.80, 30.00, 31.50, 34.00, 40.50, 41.00, 44.00, 44.10, 47.00, 59.80, 74.00, 86.00, 210.00.

* * * * *

15 All of the compounds, compositions, and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the
20 sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within
25 the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES


The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- Amtmann and Sauer, *Cancer Lett.*, 35:237-244, 1987.
- Amtmann and Sauer, *Int. J. Cancer*, 45:1113-1118, 1990.
- Amtmann *et al.*, *J. Gen. Virol.*, 66(Pt 9):1953-1960, 1985.
- 10 Amtmann, *Drugs Exp. Clin. Res.*, 22:287-294, 1996.
- Bettaieb *et al.*, *Mol. Pharmacol.*, 55:118-125, 1999.
- Chevion *et al.*, *Free Radic. Biol. Med.*, 22:411-421, 1997.
- Druker and Lydon, *J. Clin. Invest.*, 105:3-7, 2000.
- Enomoto *et al.*, *Cancer Lett.*, 155:137-144, 2000.
- 15 Furstenberger *et al.*, *Int. J. Cancer*, 43:508-512, 1989.
- Gazdar and Minna, *Proc. Natl. Acad. Sci. USA*, 98:10028-10030, 2001.
- Gibbs, *Science*, 287:1969-1973, 2000.
- Giron-Calle *et al.*, *J. Pharmacol. Exp. Ther.*, 301:87-94, 2002.
- Greenberger *et al.*, *Antioxid. Redox. Signal*, 3:347-359, 2001.
- 20 Hospers *et al.*, *Br. J. Cancer*, 80:629-638, 1999.
- Krise *et al.*, *J. Pharm. Sci.*, 88:922-927, 1999b.
- Krise *et al.*, *J. Pharm. Sci.*, 88:928-932, 1999a.
- Li *et al.*, *Proc. Natl. Acad. Sci. USA*, 95:7748-7775, 1998.
- Luberto and Hannun, *J. Biol. Chem.*, 273:14550-14559, 1998.
- 25 Luberto *et al.*, *J. Biol. Chem.*, 275:14760-14766, 2000.
- Machleidt *et al.*, *J. Exp. Med.*, 184:725-733, 1996.
- Nudelman *et al.*, *Eur. J. Med. Chem.*, 36:63-74, 2001.
- Paris *et al.*, *Science*, 293:293-297, 2001.
- Poggi *et al.*, *Curr. Probl. Cancer*, 25:334-411, 2001.
- 30 Porn-Ares *et al.*, *Exp. Cell Res.*, 235:48-54, 1997.
- Rao, In: *Xanthates and related compounds*, Marcel Dekker, Inc., NY, 1971.

- Rasmussen and Leonard, *J. Amer. Chem. Soc.*, 89(21), 5439-5445, 1967.
- Remington's Pharmaceutical Sciences, 15th ed., 33:624-652, Mack Publishing Company, Easton, PA, 1980.
- Riboni *et al.*, *J. Biol. Chem.*, 276:12797-12804, 2001.
- 5 Santana *et al.*, *Cell*, 86:189-199, 1996.
- Sauer *et al.*, *Cancer Lett.*, 53:97-102, 1990.
- Schick *et al.*, *Cancer Lett.*, 46:143-147, 1989.
- Schick *et al.*, *Cancer Lett.*, 46:149-152, 1989.
- Schutze *et al.*, *Cell*, 71:765-776, 1992.
- 10 Schutze *et al.*, *J. Exp. Med.*, 174:975-988, 1991.
- Smith and Clark, In: *Drug latention and prodrugs*, Delgado and Remers (Eds.), Lippincott-Raven Publishers, Philadelphia, 123-138, 1998.
- Smith and Rutledge, *Natl. Cancer Inst. Monogr.*, 42:141-143, 1975.
- Wang *et al.*, *Bioorg. Med. Chem.*, 6:417-426, 1998.
- 15 Young *et al.*, *N Engl J Med.* 7:299(23):1261-1266, 1978.
- Zhou *et al.*, *Int. J. Radiat. Biol.*, 77:763-772, 2001.
- Zhou *et al.*, *J. Pharmacol. Exp. Ther.*, 298:103-109, 2001.

WHAT IS CLAIMED IS:

1. A compound of formula (I)



5

(I)

wherein R is a heteroatom substituted alkyl moiety;
or a pharmaceutically acceptable salt thereof.


10

2. The compound of claim 1, wherein R is an alkyl or alkoxy moiety.

3. The compound of claim 2, wherein R is an alkoxyphosphoryl or alkoxyacyl moiety.

15


4. The compound of claim 3, wherein the compound of formula (I) is:



wherein R¹, R², and R³ are independently H or alkyl moieties;
or a pharmaceutically acceptable salt thereof.

20

5. A compound of claim 3, wherein the compound of formula (I) is:




- 5 wherein R¹ and R² are independently H or alkyl moieties;
or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

10

7. A method of treating a disease or disorder in a subject, comprising:
a) obtaining a composition comprising a compound of formula (I):



(I)

15


- wherein R is a heteroatom substituted alkyl moiety;
or a pharmaceutically acceptable salt thereof; and
b) administering a therapeutically effective amount of the composition to the subject.

20

8. The method of claim 7, wherein R is an alkyl or alkoxy moiety.


9. The method of claim 8, wherein R is an alkoxyphosphoryl or alkoxyacyl moiety.

5 10. The method of claim 9, wherein the compound of formula (I) is:



wherein R¹, R² and R³ are independently H or alkyl moieties;
or a pharmaceutically acceptable salt thereof.

10 11. The method of claim 9, wherein the compound of formula (I) is:



wherein R¹ and R² are independently H or alkyl moieties;
or a pharmaceutically acceptable salt thereof.

15

12. The method of claim 7, wherein the subject is a mammal.

13. The method of claim 12, wherein the mammal is a human.

14. The method of claim 7, wherein the disease is an autoimmune disease, and
inflammatory disease, a neurodegenerative disease, a disease associated with ischemia
and reperfusion injury, trauma, atherosclerosis, ageing, cancer, viral infection, UV-
20 induced radiation injury, or ionizing radiation-induced injury.

15. The method of claim 14, wherein the autoimmune disease is systemic lupus, chronic thyroiditis, Graves disease, autoimmune gastritis, autoimmune hemolytic anemia, autoimmune neutropenia, or thrombocytopenia.

5 16. The method of claim 14, wherein the inflammatory disease is rheumatoid arthritis, organ transplant rejection, graft versus host disease, endotoxemia, sepsis, septic shock, uveitis, inflammatory peritonitis, or pancreatitis.

17. The method of claim 14, wherein the neurodegenerative disease is Alzheimer disease, Parkinson's disease, Huntington's disease, Kennedy's disease, prion disease, multiple sclerosis, amyotrophic lateral sclerosis, or spinal muscular atrophy.

10 18. The method of claim 14, wherein the disease associated with ischemia and reperfusion injury is a stroke or myocardial infarction.

15 19. The method of claim 14, wherein the cancer is breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, leukemia, stomach cancer, pancreatic cancer, testicular cancer lymphoma, or multiple myeloma.


20. The method of claim 14, wherein the trauma is traumatic brain injury spinal cord injury, or burn injury.

20 21. The method of claim 7, wherein the disease or disorder is a disease or disorder associated with oxidative stress.

25 22. The method of claim 7, wherein administration of the composition comprises oral administration, intravenous administration, intraarterial administration, topical administration, intratumoral administration, regional administration, intrathecal administration, intraperitoneal administration, intraocular administration, or inhalational administration.

23. A method of protecting normal tissue in a subject from the toxicity associated with treatment of a disease with ionizing radiation or a chemotherapeutic agent, comprising:

- a) obtaining a composition comprising a compound of formula (I):



(I)

wherein R is a heteroatom substituted alkyl moiety;


or a pharmaceutically acceptable salt thereof; and

- b) concurrently or consecutively administering to the subject a prophylactically effective amount of the composition and the ionizing radiation or chemotherapeutic agent.

24. The method of claim 23, wherein R is an alkyl or alkoxy moiety.

25. The method of claim 24, wherein R is an alkoxyphosphoryl or alkoxyacyl moiety.


26. The method of claim 25, wherein the compound of formula (I) is:



wherein R¹, R² and R³ are independently H or alkyl moieties;

or a pharmaceutically acceptable salt thereof.

27. The method of claim 25, wherein the compound of formula (I) is:



wherein R¹ and R² are independently H or an alkyl moieties;
or a pharmaceutically acceptable salt thereof.

5 28. The method of claim 23, wherein the subject is a mammal.

29. The method of claim 28, wherein the mammal is a human.

30. The method of claim 23, wherein the disease is an autoimmune disease,
and inflammatory disease, a neurodegenerative disease, a disease associated with
ischemia and reperfusion injury, trauma, atherosclerosis, ageing, cancer, or a viral
10 infection.

31. The method of claim 30, wherein the disease is cancer.

32. The method of claim 31, wherein the cancer is breast cancer, lung cancer,
prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer,
renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder
15 cancer, uterine cancer, lymphatic cancer, leukemia, stomach cancer, pancreatic cancer,
testicular cancer lymphoma, or multiple myeloma.

33. The method of claim 23, wherein the chemotherapeutic agent is
doxorubicin, daunorubicin, methotrexate, tamoxifen, paclitaxel, topotecan, LHRH,
mitomycin C, etoposide, tomudex, podophyllotoxin, mitoxantrone, colchicine, endostatin,
20 fludarabin, mitomycin, actinomycin D, bleomycin, cisplatin, VP16, an enediyne, taxol,
vincristine, vinblastine, carmustine, melphalan, cyclophosphamide, chlorambucil,
busulfan, lomustine, 5-fluorouracil, gemcitabine, BCNU, or camptothecin.

34. The method of claim 23, wherein administering a prophylactically
effective amount of the composition comprises oral administration, intravenous


administration, intraarterial administration, topical administration, local administration into a tumor, intrathecal administration, intraperitoneal administration, intraocular administration, or inhalational administration.

5 35. The method of claim 23, wherein the prophylactically effective amount of the composition and the ionizing radiation or chemotherapeutic agent are concurrently administered.

36. The method of claim 23, wherein the prophylactically effective amount of the composition and the ionizing radiation or chemotherapeutic agent are consecutively administered.

10 37. A method of treating a disease or disorder in a subject, comprising:

a) obtaining a composition comprising a compound of formula (I):



(I)

15 wherein R is a heteroatom substituted alkyl moiety;
or a pharmaceutically acceptable salt thereof; and


b) concurrently or consecutively administering a therapeutically effective amount of the composition and ionizing radiation or a chemotherapeutic agent to the subject.

20

38. The method of claim 37, wherein R is an alkyl or alkoxy moiety.

39. The method of claim 38, wherein R is an alkoxyphosphoryl or alkoxyacyl moiety.


40. The method of claim 39, wherein the compound of formula (I) is:



5

wherein R¹, R², and R³ are independently H or alkyl moieties;
or a pharmaceutically acceptable salt thereof.

41. The method of claim 39, wherein the compound of formula (I) is:



10

wherein R¹ and R² are independently H or alkyl moieties;
or a pharmaceutically acceptable salt thereof.

42. The method of claim 37, wherein the subject is a mammal.

43. The method of claim 42, wherein the mammal is a human.

15

44. The method of claim 37, wherein the disease is cancer.

20

45. The method of claim 44, wherein the cancer is breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, leukemia, stomach cancer, pancreatic cancer, testicular cancer lymphoma, or multiple myeloma.

46. The method of claim 37, wherein the therapeutically effective amount of the composition and the ionizing radiation or chemotherapeutic agent are concurrently administered.

5 47. The method of claim 36, wherein the therapeutically effective amount of the composition and the ionizing radiation or chemotherapeutic agent are consecutively administered.

ABSTRACT

Compounds that are heteroatom substituted alkyl derivatives of tricyclodecan-9-yl-xanthogenate, and pharmaceutical compositions of these compounds, are disclosed. Methods of treating a disease or disorder in a subject and methods of protecting normal
5 tissues in a subject from toxicity associated ionizing radiation or chemotherapy using compositions comprising these novel compounds are also disclosed. The invention also concerns methods of treating a disease or disorder in a subject using compositions that include these novel compounds while concurrently or consecutively treating the subject with ionizing radiation or a chemotherapeutic agent.

FIG. 1A

D609





FIG. 1B


S-(Alkoxyphosphoryl) D609



R¹, R², R³ = H, alkyl

FIG. 1C

S-(Alkoxyacyl) D609



R¹, R², = H, alkyl

FIG. 2




FIG. 3




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7A




FIG.. 7B




FIG. 7 C




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13




FIG. 14





FIG. 15




FIG. 16A




FIG. 16B





FIG. 16C



Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/033255

International filing date: 08 October 2004 (08.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/509,700
Filing date: 08 October 2003 (08.10.2003)

Date of receipt at the International Bureau: 17 January 2005 (17.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.